Podcasts about pharmacy times

Can psychedelics revolutionize weight loss? Explore how psilocybin, the active compound in magic mushrooms, is gaining attention as a potential breakthrough in managing cravings, emotional eating, and metabolism. From the science behind microdosing to industry investments by companies like NeonMind Biosciences, we dive into whether psychedelics could be the next big thing in the $100 billion weight loss market. But with legal hurdles, safety concerns, and ethical challenges, is this dream too far from reality? Watch to uncover the facts, the hype, and the future of psilocybin-based therapies! Join the Groove Guide Today and Transform Your Wellness Journey!

Pharmacy CrossRoads is celebrating an incredible year of more than 60+ interviews with people in independent community pharmacy making a difference through technology, practice innovation, and networking to build stronger community pharmacies. Pharmacy CrossRoads is one of the most popular podcasts on the Pharmacy Podcast Network with an impressive 40,000+ downloads this podcast is one of the best shows about Independent Community Pharmacy.  With an increase of pharmacy deserts throughout the country threatening access to life saving medicaitons and primary care providers driven to the brink exhaustion with so many patients needing access to care, the community pharmacy is more importatnt than ever before. Pharmacy CrossRoads is expanding its team. Started by Bruce Kneeland through the Pharmacy Podcast Network, the popularity of the show and themes will bring our listeners 4 new Hosts, each taking a theme which has personally impacted their work in community pharmacy. Adam Robinson We have Dr. Adam Robinson, PharmD, known as the "Work flow Whisperer" as a pharmacy owner of Save Rite Drugs in Radcliff KY, Adam will be brining real-world experieces of pharmacy ownership. Kris Rhea With over 15 years of pharmacy and healthcare business experience, Director of Business Development of Pharmacy Marketplace, Kris Rhea is joining the Hosts of Pharmacy CrossRoads to drive content about the business of pharmacy's impact on independent owners. Shahida Choudhry Owner of The Palms Pharmacy in Tampa FL, member of the board of directors with Independent Pharmacy Cooperative, and voted 4 years in a row as one of the "50 Most Influential People in Pharmacy" Dr. Shahida Choudhry PharmD is joining Pharmacy CrossRoads to participate in discussions about moving community pharmacy forward and away from the clutches of the PBMs hampering the effectiveness of our Pharmacists in communites across the country. Stacy Hall Pharmacy Business Executive Stacy Hall, MBA is the CEO of the Florida Pharmacy Association which brings Pharmacy CrossRoads significant insights from state policies, government programs, and a diverse knowledge of multiple sectors of pharmacy care. As CEO of the FPA, Stacy is in conistent communitcations with national organizations like the National Alliance of State Pharmacy Associations (NASPA) and the American Pharmacists Association (APhA). This will bring Pharmacy CrossRoads listeners an indepth conversation about issues impacting independent community pharmacies. "It's been an honor to work with Bruce. With over 40 years of Pharmacy Business experience and as a prolific writer for Pharmacy Times, Drug Topics, Computer Talk, Dispense Times, and other publications, podcasting was a natural fit to draw out Bruce's insights and guidance of relevant conversations about community pharmacy in the U.S." --stated Todd Eury, CEO of RxPR, LLC dba Pharmacy Podcast Network, "There's no other host on the PPN that's connected better with businesses looking to use podcasting as education for pharmacy onwers in a meaninful way which doenst sound like a boring commerical. We're looking forward to adding our 4 new podcast hosts to one of our most popular shows." To listen to the latest Pharmacy CrossRoads podcast featuring the new hosts, click here: (LINK) Subscribe on Spotify, Apple, and all podcast directories. About Pharmacy Podcast Network (PPN) The only platform of its kind, PPN offers a comprehensive range of podcasts and content related to pharmacy, covering topics such as careers, compounding, education, hospital and health system issues, politics, professional development, retail and community pharmacy, senior and long-term care, specialty pharmacy, and student pharmacists.

Pharmacy CrossRoads is celebrating an incredible year of more than 60+ interviews with people in independent community pharmacy making a difference through technology, practice innovation, and networking to build stronger community pharmacies. Pharmacy CrossRoads is one of the most popular podcasts on the Pharmacy Podcast Network with an impressive 40,000+ downloads this podcast is one of the best shows about Independent Community Pharmacy.  With an increase of pharmacy deserts throughout the country threatening access to life saving medicaitons and primary care providers driven to the brink exhaustion with so many patients needing access to care, the community pharmacy is more importatnt than ever before. Pharmacy CrossRoads is expanding its team. Started by Bruce Kneeland through the Pharmacy Podcast Network, the popularity of the show and themes will bring our listeners 4 new Hosts, each taking a theme which has personally impacted their work in community pharmacy. Adam Robinson We have Dr. Adam Robinson, PharmD, known as the "Work flow Whisperer" as a pharmacy owner of Save Rite Drugs in Radcliff KY, Adam will be brining real-world experieces of pharmacy ownership. Kris Rhea With over 15 years of pharmacy and healthcare business experience, Director of Business Development of Pharmacy Marketplace, Kris Rhea is joining the Hosts of Pharmacy CrossRoads to drive content about the business of pharmacy's impact on independent owners. Shahida Choudhry Owner of The Palms Pharmacy in Tampa FL, member of the board of directors with Independent Pharmacy Cooperative, and voted 4 years in a row as one of the "50 Most Influential People in Pharmacy" Dr. Shahida Choudhry PharmD is joining Pharmacy CrossRoads to participate in discussions about moving community pharmacy forward and away from the clutches of the PBMs hampering the effectiveness of our Pharmacists in communites across the country. Stacy Hall Pharmacy Business Executive Stacy Hall, MBA is the CEO of the Florida Pharmacy Association which brings Pharmacy CrossRoads significant insights from state policies, government programs, and a diverse knowledge of multiple sectors of pharmacy care. As CEO of the FPA, Stacy is in conistent communitcations with national organizations like the National Alliance of State Pharmacy Associations (NASPA) and the American Pharmacists Association (APhA). This will bring Pharmacy CrossRoads listeners an indepth conversation about issues impacting independent community pharmacies. "It's been an honor to work with Bruce. With over 40 years of Pharmacy Business experience and as a prolific writer for Pharmacy Times, Drug Topics, Computer Talk, Dispense Times, and other publications, podcasting was a natural fit to draw out Bruce's insights and guidance of relevant conversations about community pharmacy in the U.S." --stated Todd Eury, CEO of RxPR, LLC dba Pharmacy Podcast Network, "There's no other host on the PPN that's connected better with businesses looking to use podcasting as education for pharmacy onwers in a meaninful way which doenst sound like a boring commerical. We're looking forward to adding our 4 new podcast hosts to one of our most popular shows." To listen to the latest Pharmacy CrossRoads podcast featuring the new hosts, click here: (LINK) Subscribe on Spotify, Apple, and all podcast directories. About Pharmacy Podcast Network (PPN) The only platform of its kind, PPN offers a comprehensive range of podcasts and content related to pharmacy, covering topics such as careers, compounding, education, hospital and health system issues, politics, professional development, retail and community pharmacy, senior and long-term care, specialty pharmacy, and student pharmacists.

Welcome to another episode of "This Week in Pharmacy"! Your host, Todd Eury, is joined by a special co-host, Saleem Shah, the CEO of the Collaborative Patient Care Group (CPCG). Together, they bring you the latest and greatest in pharmacy news and insights. News of the Week: Pharmacy Educators and Social Media: We dive into an intriguing story from Pharmacy Times about how pharmacy educators are harnessing the power of social media to inspire and engage the next generation of pharmacists. Find out how these innovative approaches are shaping the future of pharmacy education. AscellaHealth Recognition: AscellaHealth has been highlighted in the SHSMD Calendar of Healthcare Observances for their efforts in promoting Gene Therapy and Specialty Pharmacy Awareness Month. We discuss what this recognition means for the field and how it reflects ongoing advancements and awareness in these critical areas. Featured Guest Interview: Dr. Tenille Davis, PharmD: We are thrilled to welcome Dr. Tenille Davis, PharmD, the Chief Advocacy Officer for the Alliance for Pharmacy Compounding. Dr. Davis will share her insights on the current state of pharmacy compounding, its challenges, and future directions. Upcoming Events: PPN at NASP 2024: Mark your calendars for the NASP 2024 conference in Nashville from October 6-9! We'll be at the NASP booth, and we invite you to connect with us and be part of our Podcast Spotlight podcast series. Don't miss this opportunity to engage with the pharmacy community and catch our live podcast recordings. Connect with Us: Follow us on social media for updates and highlights from the episode. Join the conversation and share your thoughts on the topics discussed. Tune in for a dynamic episode filled with valuable information and engaging discussions! Subscribe today: https://linktr.ee/PharmacyPodcast

We kick off 'This Week in Pharmacy' with a news review starting with an interview from Pharmacy Times with Rina Shah, SVP of Walgreens about -- "Sustainable Care Models Must Expand Role of Pharmacist" Rina discussed what the future of sustainable care models in the pharmaceutical industry. We also note the article titled: "Community Pharmacists Can Impact Disparities in Care Delivery" Drug Topics interviews Jasmine Perry, PharmD, senior clinical pharmacist, professional engagement and quality at Blue Cross and Blue Shield of North Carolina.  Access In some rural areas of the United States, pharmacists are the only health care providers that a community can access. Our guest, Vincent Grippi is the Founder and CEO of Grippi Media. He brings over 16 years of experience helping companies leverage digital marketing to accelerate business growth, reach new customers and build brand equity.    Vincent has designed and implemented digital marketing strategies for startups and Fortune 500 companies both agency-side and in-house. His work has been featured in AdWeek, Business Insider, Fierce Healthcare, Marketing Dive and more.   

Shifting Your Mindset for Success with Dr. Lorenka Joseph, PharmD on 'This Week in Pharmacy' -- It's June 21st, 2024, and it's the Summer Solstice, the Longest Day of the Year occurring when one of Earth's poles is tilted toward the sun at its most extreme angle, and due to Earth's tilt, this happens twice a year.  Thanks to RxMile for sponsoring today's TWIRx, logistics strategies and technology, this software sells itself. With the expansion of long term care at home, and the need for more pharmacy delivery in areas with pharmacy closures, it's time to talk with Kunal and his team. This is a game changer.  NEWS: The New York Times reported on the impact to public health of the PBMs middlement, causing massive struggles for pharmacy care throughout the nation.  Pharmacy closures in Michigan and Ohio causing major concerns for the needs of millions of people.  Maternal Health Disparities, Role of Pharmacists in Improving Outcomes, from Pharmacy Times, interview with Rebeca Snead, PharmD.  Our feature interview with Dr. Lorneka Joseph PharmD, helping healthcare professionals Shift Your Mindset for Success! 

On this episode of Pharmacy Focus, experts discuss World Psychedelics Day, which is June 20. Experts will also discuss goals of World Psychedelics Day in increasing awareness and appreciation of psychedelics' therapeutic potential while honoring traditional knowledge. Experts cover the history of psychedelics, current research on psychedelic therapies for conditions like PTSD and depression, and future directions. Proper education, screening, medication management and harm reduction practices are highlighted as best ways that pharmacists can get involved. Guests Include: Mark Achbar, WPD Founder Sarah Butterfield, WPD Creative Director Rev. Shannon Smadella, WPD Operations & Partnerships Director Sandra Dreisbach, PhD, WPD Ethics Director Dennis Mckenna, Director and President of the Mckenna Academy Kevin Lanzo, PharmD, co-founder of the Psychedelic Pharmacists Association (PPA) Kristin Speer, PharmD, BCPS, co-founder of the PPA References 1. Pharmacy Times. Survey Shows 65% of Affected Americans Want Access to Psychedelic Treatments for Mental Health Conditions. February 8. 2022. Accessed June 13, 2024. https://www.pharmacytimes.com/view/survey-shows-65-of-affected-americans-want-access-to-psychedelic-treatments-for-mental-health-conditions 2. Gallagher A. Psychedelic Medicine Could Fill Care Gap in Psychiatric Care. Pharmacy Times. April 10, 2024. Accessed June 13, 2024. https://www.pharmacytimes.com/view/psychedelic-medicine-could-fill-care-gap-in-psychiatric-care 3. Gallagher A. Is 2024 the Year for Psychedelic Medicine?. Pharmacy Times. April 4, 2024. Accessed June 13, 2024. https://www.pharmacytimes.com/view/is-2024-the-year-for-psychedelic-medicine- 4. Antrim A. FDA Advisory Panel Rejects MDMA-Assisted Therapy for PTSD. Pharmacy Times. June 4, 2024. Accessed June 13, 2024. https://www.pharmacytimes.com/view/fda-advisory-panel-rejects-mdma-assisted-therapy-for-ptsd

Christian Lillis, Co-Founder and CEO of the Peggy Lillis Foundation is a patient advocate in the fight against C. diff infection. Clostridium difficile is an opportunistic infection of the gut that often occurs after taking antibiotics and can lead to life-threatening complications. Christian shares his personal story of losing his mother to C. diff and highlights the progress made in raising awareness and the development of new treatments for the infection. The Peggy Lillis Foundation emphasizes the importance of patient voices in shaping infectious disease policies and research and the need for community support to fight C. diff and other preventable infectious diseases. Christian explains, "Last time we did our most recent C. diff awareness month campaign in November, it was our most successful one yet. We reached around 23 million people through a mix of earned, print, video, and podcast media and a strong social media campaign. We also had it bolstered by media partnerships with Contagion Live and Pharmacy Times. As part of our programming for the month, we held a virtual town hall, and about 200 people attended. More than half of them were C. diff patients, survivors, and family members." "Other progress was at the end of 2022, and then in early 2023, two new therapies. Technically, they are classified as preventative by the FDA, but they are basically microbiome restoration therapies. As I said earlier, when you take antibiotics, there can be other causes. Still, when your gut microbiome, gut bacteria, and viruses get out of whack or depleted, you become very vulnerable to C. diff. And a reason why people struggle to get over C. diff is because their gut microbiome remains degraded. So these new two therapies, one is done by enema, one is given by capsule over several days, it's a really huge change for people who are battling recurrent C. diff."  #CDiff #PeggyLillisFoundation #ClostridiumDifficile #CDifficile #PatientAdvocacy #CdiffAwarenessMonth cdiff.org Download the transcript here

Christian Lillis, Co-Founder and CEO of the Peggy Lillis Foundation is a patient advocate in the fight against C. diff infection. Clostridium difficile is an opportunistic infection of the gut that often occurs after taking antibiotics and can lead to life-threatening complications. Christian shares his personal story of losing his mother to C. diff and highlights the progress made in raising awareness and the development of new treatments for the infection. The Peggy Lillis Foundation emphasizes the importance of patient voices in shaping infectious disease policies and research and the need for community support to fight C. diff and other preventable infectious diseases. Christian explains, "Last time we did our most recent C. diff awareness month campaign in November, it was our most successful one yet. We reached around 23 million people through a mix of earned, print, video, and podcast media and a strong social media campaign. We also had it bolstered by media partnerships with Contagion Live and Pharmacy Times. As part of our programming for the month, we held a virtual town hall, and about 200 people attended. More than half of them were C. diff patients, survivors, and family members." "Other progress was at the end of 2022, and then in early 2023, two new therapies. Technically, they are classified as preventative by the FDA, but they are basically microbiome restoration therapies. As I said earlier, when you take antibiotics, there can be other causes. Still, when your gut microbiome, gut bacteria, and viruses get out of whack or depleted, you become very vulnerable to C. diff. And a reason why people struggle to get over C. diff is because their gut microbiome remains degraded. So these new two therapies, one is done by enema, one is given by capsule over several days, it's a really huge change for people who are battling recurrent C. diff."  #CDiff #PeggyLillisFoundation #ClostridiumDifficile #CDifficile #PatientAdvocacy #CdiffAwarenessMonth cdiff.org Listen to the podcast here

On this episode, experts discuss the role of celebrity endorsements and trusted local figures in addressing vaccine hesitancy. Experts commented on studies examining how peer influencers and endorsements from figures like Dr. Fauci can increase vaccine acceptance by making the issues more relatable. However, they also noted the need to understand different factors contributing to hesitancy as well as ensuring endorsements match the right target audience and local context to be most effective. The podcast explored both the potential and limitations of celebrity marketing in vaccine promotion and uptake. Experts Include: Sean Young, PhD, executive director of the University of California Institute for Prediction Technology; Alfred L'Altrelli, PharmD, CFMC, MBA, the senior director of pharmacy at UPMC Presbyterian-Shadyside; and Troy Trygstad, PharmD, PhD, MBA, the executive director of CPESN USA. Key Takeaways 1. The podcast discussed vaccine hesitancy and how celebrity endorsements can be used to address it. Experts commented on factors like personal beliefs, social networks, and online misinformation that contribute to hesitancy. 2. Pharmacists noted that conversations with patients have shifted from vaccine development to side effects and efficacy as awareness has increased. Misinformation remains a challenge. 3. Studies found that peer-led online communities and celebrity endorsements, like from Dr. Fauci, can increase vaccine acceptance and confidence. Experts emphasized matching the right celebrity to the target audience. 4. While celebrity endorsements may not directly drive people to pharmacies, they can make vaccination more relatable and impact attitudes. Local media personalities were suggested as alternative endorsers. 5. The podcast explored both the potential benefits but also limitations of celebrity endorsements in influencing public health decisions around vaccines. Understanding audience trust was a key consideration. References 1. Gallagher A. Celebrities Don't Persuade Patients to Get Vaccinated; Pharmacists Do. Pharmacy Times. January 18, 2024. Accessed February 15, 2024. https://www.pharmacytimes.com/view/celebrities-don-t-persuade-patients-to-get-vaccinated-pharmacists-do 2. Bokemper SE, Huber GA, Gerber AS, James EK, Omer SB. Timing of COVID-19 vaccine approval and endorsement by public figures. Vaccine. 2021;39(5):825-829. doi:10.1016/j.vaccine.2020.12.048

On this month's episode, Pharmacy Times provides a recap of the latest advancements in hematology and breast cancer, shared at the 2023 American Society of Hematology conference and the San Antonio Breast Cancer Symposium conference.

We did not want to stand y'all up two weeks in a row, so here is a special release from the Patreon.  It starts a little slow then Producer Mike and I find our stride.  But if you've been on the fence about becoming a supporter maybe this will push you over the edge (in a good way).   There's a link below or you can simply search The Lore of the South on the Patreon site or app.Hey Tare, if you're out there I still have your little goody bad ready to ship. Email us your info and it will be on its way.loreofthesouth@gmail.comhttps://patreon.com/theloreofthesouth?utm_medium=clipboard_copy&utm_source=copyLink&utm_campaign=creatorshare_creator&utm_content=join_linkcitation 7 unusual ancient medical techniques - history. (n.d.). https://www.history.com/news/7-unusual-ancient-medical-techniques Beheler, T. (2022, April 27). 10 strange medical practices from history: Headlines and heroes. The Library of Congress. https://blogs.loc.gov/headlinesandheroes/2022/04/10-strange-medical-practices-from-history/ Karen Berger, P. (2021, March 5). Pharmacy's past: The soothing syrup known for causing death in thousands of babies. Pharmacy Times. https://www.pharmacytimes.com/view/pharmacys-past-the-soothing-syrup-known-for-causing-death-in-thousands-of-babies- Lagay, F. (2002, July 1). The legacy of Humoral Medicine. Journal of Ethics | American Medical Association. https://journalofethics.ama-assn.org/article/legacy-humoral-medicine/2002-07 List of reasons for admission to an insane asylum from the late 1800s. DangerousMinds. (2015, May 11). https://dangerousminds.net/comments/list_of_reasons_for_admission_to_an_insane_asylum MediLexicon International. (n.d.). Medieval coffin birth: A modern medical mystery. Medical News Today. https://www.medicalnewstoday.com/articles/321433#Ongoing-risks-in-pregnancy Wikimedia Foundation. (2023, March 21). Teething. Wikipedia. https://en.wikipedia.org/wiki/Teething Support the show

On this month's episode, Pharmacy Times covers the Academy of Managed Care Pharmacy Nexus 2023 conference, highlighting the updates on biosimilars. Interviews include: Chelsee Jensen, PharmD, BCPS a senior pharmacy specialist and pharmaceutical formulary manager at Mayo Clinic, Prerakkumar Parikh, PharmD, director of Specialty Clinical Solutions at Magellan Rx Management, and Kimberly Maxfield, PhD, from the FDA. For more Nexus 2023 coverage, visit pharmacytimes.com. Key Takeaways: Jensen discusses biosimilar approval updates, trends biosimilars, and what health care professionals can expect in the future. Parikh discusses the impact of interchangeable biosimilars, their cost-saving benefits, and the influx of biosimilars into pharmacy. Maxfield discusses the role pharmacists can take to reassure patients when switching to a biosimilar and the future of biosimilar development.

In an interview with Pharmacy Times, Nikhil Palekar, MD, director of the Stony Brook Center of Excellence for Alzheimer Disease, director of the Stony Brook Division for Geriatric Psychiatry, and director of the Stony Brook Alzheimer Disease clinical trials program, discussed the FDA approval of lecanemab-irmb (Leqembi, Eisai) and what this means for those who have Alzheimer Disease. Although the treatment is not a cure and cannot reverse early Alzheimer disease, Palekar said it could give patients crucial more time to join other clinical trials investigating potential treatments.

On this bonus episode, Pharmacy Times spoke with Chris Zaleski from the University of Nebraska Medical Center and James Sullivan, MD, from the Methodist Health System, about their presentations at the American Association of Pharmacy Technicians Convention 2023.

This week on Pharm5: Novo Nordisk insulin price cuts Akorn Pharma closing, potential drug shortages Zavzpret (zavegepant) migraine nasal spray Daybue (trofinetide) for Rett Syndrome 2023 Match Results Connect with us! Listen to our podcast: Pharm5 Follow us on Twitter: @LizHearnPharmD References: Novo Nordisk to lower U.S. prices of several pre-filled insulin pens and vials up to 75% for people living with diabetes in January 2024. Novo Nordisk. http://bit.ly/42hziHz. Accessed March 16, 2023. Lilly cuts insulin prices by 70% and caps patient insulin out-of-pocket costs at $35 per month. Eli Lilly and Company. https://bit.ly/3ZQXVcf. Published March 1, 2023. Accessed March 16, 2023. Murphy T. Novo Nordisk plans price cuts for several insulins. AP NEWS. http://bit.ly/3JNzgjz. Published March 14, 2023. Accessed March 16, 2023. Kekatos M, Bakshi N, Coburn J. Nationwide shortage of asthma medication albuterol could worsen in hospitals. ABC News. https://bit.ly/3JfD1wA. Published March 9, 2023. Accessed March 16, 2023. Supply chain disruption due to manufacturer closure: Akorn Pharmaceuticals ceases operations. End Drug Shortages Alliance. https://bit.ly/3JqLZHi. Published March 7, 2023. Accessed March 16, 2023. Pfizer's Zavzpret™ (zavegepant) Migraine Nasal Spray Receives FDA Approval. Pfizer. http://bit.ly/42kQJag. Published March 10, 2023. Accessed March 16, 2023. Lipton RB, Croop R, Stock DA, et al. Safety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine in the USA: A phase 3, double-blind, randomised, placebo-controlled multicentre trial. The Lancet Neurology. 2023;22(3):209-217. doi:10.1016/s1474-4422(22)00517-8 Sargent J, Kirchner JR, Davis R, Kirkhart B. Oral sumatriptan is effective and well tolerated for the acute treatment of migraine: results of a multicenter study. Neurology. 1995;45(8 Suppl 7):S10-S14. Center for Drug Evaluation and Research. FDA approves first treatment for Rett syndrome. U.S. Food and Drug Administration. http://bit.ly/3TjSD6U. Accessed March 16, 2023. Aislinn Antrim E. FDA approves Trofinetide for treatment of Rett syndrome in adult, pediatric patients. Pharmacy Times. http://bit.ly/40fK3bq. Published March 13, 2023. Accessed March 16, 2023. ASHP match statistics. ASHP Match | Statistics of the Match. http://bit.ly/42e4Ga1. Published March 15, 2023. Accessed March 16, 2023. Schedule of dates. ASHP Match | Schedule. https://bit.ly/3I8MJA7. Published March 15, 2023. Accessed March 16, 2023.

hello, Hello, HELLO friends!  We are so excited to speak with Dr. Christina Madison! We have been her fans for a long time; she is killing the game and representing pharmacy and Black Girl Magic from the desert to the White House. Listen to the latest news on Monkey pox, HIV/AIDS, COVID-19, and how public health is helping keep us safe. Also, go to www.knowyourpharmacist.org  for a free download of 10 Questions to Ask Your Pharmacist! Here's what you'll learn in this episode: 1.     Who is still SWAC? 2.     Will Justice be served for Atatiana Jefferson? 3.     Grandma is always right; how to always wear your crown with pride, beauty, and intellect. 4.     What is Public Health, and how does it serve the most vulnerable in society and address health disparities? 5.     Know your HIV status. 6.     Be informed about new therapies for PrEP and PeP and who is eligible to receive them 7.     Update on the HIV/AIDS epidemic, syphilis uprising, monkeypox, and other communicable diseases.   Links ·       3ftlinks.com ·       Buymeacoffee.com/3friendsTALK About our Guest: ·       Christina Madison, PharmD, FCCP, AAHIVP, is a TEDx Speaker, Founder, and CEO of The Public Health Pharmacist®, PLLC, a public health consulting firm, and a clinical pharmacist specializing in public health with a focus on communicable diseases and public health. Dr. Madison has received multiple awards and recognitions including being named Las Vegas Weekly: Women Influencing Nevada 2022 Covergirl and Honoree, 50 Most Influential Pharmacy Leaders (Top 10) by the Pharmacy Podcast Network for 2021, National Association of Women Business Owners (NAWBO) Southern Nevada Chapter Women of Distinction Finalist (Health Category), Nevada State Board of Pharmacy Challenge Coin Recipient, Awarded for Exemplary Efforts During COVID-19 Pandemic Response, 2021 Greatest Medical Minds by Real Vegas Magazine, 2020 Educator Healthcare Hero by Nevada Business Magazine recognizing unsung heroes in the healthcare working on the frontline (featured in September 2020 issue), Pharmacy Times® and Parata Systems 2020 Next-Generation Pharmacist Honoree (Civic Leader Category), named one of the Top 25 Healthcare Influencers by Las Vegas Entrepreneurs Magazine in June 2020, and Pharmacy Times® “Pharmacy Hero” in May 2020 for her patient education and pharmacy advocacy during COVID19.   ·       She has also been recognized for her patient counseling skills and public health/vaccine advocacy. As a past President of the Nevada Public Health Association, she has been asked to share her clinical public health and infectious disease expertise with Local, State, and International Media outlets and NGO's. Dr. Madison has been featured in over 200+ on-air TV appearances since the beginning of the pandemic related to public health. She has an intimate knowledge of the impact public health messaging, policy, and legislation can have on communities. A trusted and valued healthcare professional with 15 years of experience in Public Health and 18 years of experience as a pharmacy professional. An advocate for victims of human trafficking, vulnerable populations, and the underserved, Dr. Madison is a graduate of the 2021 Las Vegas FBI Citizens Academy.   ·       Dr. Madison is currently an Associate Professor of Pharmacy Practice with Roseman University of Health Sciences (RU), College of Pharmacy. She maintains two active clinical practices with Huntridge Family Clinic, which focuses on the LGTBQ community and is one of the largest providers of HIV prevention and gender affirming care services in the State of Nevada as well as Volunteers in Medicine of Southern Nevada (VMSN) where she offers immunization and communicable disease care. Dr. Madison is past director of Roseman University of Health Sciences COVID-19 Vaccine Operations, Logistics, Distribution, and Administration as well as the Point of Contact for the State of Nevada for COVID vaccines. She has personally facilitated the administration of over 12,000 doses of COVID-19 vaccine in the Southern Nevada community. Advocating for public health and the profession of pharmacy to improve the health and wellness of vulnerable populations and the underserved is her passion and mission.   Enjoying the show? Leave us a review on your favorite podcast platform and connect with 3 friends TALK: ·       www.youtube.com/3friendsTALK ·       www.3friendsTALK.com ·       www.instagram.com/3friendsTALK ·       www.facebook.com/3friendsTALK  

Join the Anxiety Chicks this week with special guest Dr. Jen! Dr. Jennifer Bourgeois is an Integrative Health Pharmacist specializing in Nutrition and Mineral Balancing. She is the CEO of Well & Free and the founder of She Thrives and the STRESSED MOM™ Transformation, where she helps busy moms optimize health and upgrade well-being with proprietary protocols. Dr Jennifer is a Fellow with the American Institute of Stress and has over 15 years of experience in the health and wellness industry.  Dr. Jennifer is also a best selling author and has been featured in Pharmacy Times, Drug Topics, VeryWell Family, Health.com, and MJH Life Sciences as well as numerous podcast episodes. In addition to her professional roles, Dr. Jennifer is the founder of a non-profit, A New View, that recycles and repurposes used eyeglasses. She is also a devoted wife and mother who is passionate about her faith. You can find more about Dr. Jen on instagram at @drjenbourgeois This weeks sponsor: Hello Fresh: Go to HelloFresh.com/anxietychicks65 and use code anxietychicks65 for 65% off plus free shipping Follow us: @theanxietychicks @health_anxiety @theanxietyhealer

This week on Pharm5: Adult Immunization Schedule 2023 Pediatric Immunization Schedule 2023 Rapid acting antidepressant, Zuranolone 2022 NAPLEX/MPJE Pass Rates State of the Union Address Connect with us! Listen to our podcast: Pharm5 Follow us on Twitter: @LizHearnPharmD References: Murthy N, Wodi AP, Cineas S, Ault KA. Recommended Adult Immunization Schedule, United States, 2023. https://doi.org/10.7326/M23-0041. Ann Int Med. 2023. The 5 biggest changes in the 2023 adult vaccine schedules. Medscape. http://bit.ly/40WmmX5. Published February 9, 2023. Accessed February 9, 2023. Committee on Infectious Diseases. Recommended Childhood and Adolescent Immunization Schedule: United States, 2023. https://doi.org/10.1542/peds.2022-061029. Pediatrics. 2023. Swift D. AAP approves 2023 Child and adolescent immunization schedule. Medscape. http://bit.ly/3RMFhPD. Published February 9, 2023. Accessed February 9, 2023. Biogen and Sage Therapeutics announce FDA accepts filing of New Drug Application and grants priority review of Zuranolone in the treatment of major depressive disorder and postpartum depression. Biogen. http://bit.ly/3HR6pbB. Accessed February 9, 2023. Data & Research. National Association of Boards of Pharmacy. http://bit.ly/40W5qQv. Accessed February 9, 2023. Aislinn Antrim E. State of the union address focuses on affordable health care, cost of insulin. Pharmacy Times. http://bit.ly/3jPc4qT. Published February 8, 2023. Accessed February 9, 2023. Full 2023 President Biden State of the Union Annotated and fact checked. CNN. http://bit.ly/3YlJs7w. Accessed February 9, 2023.

This week on Pharm5: Walmart, CVS Claim Pharmacist Shortage Changes to Paxlovid, Lagevrio, and COVID vaccines EzriCare eyedrops linked to bacterial outbreak New FDA approvals: Jayprica, Orserdu, Jesduvroq GoodRx sells health info to advertisers Connect with us! Listen to our podcast: Pharm5 Follow us on Twitter: @LizHearnPharmD References: Valinsky J. CVS and Walmart Cut Pharmacy Hours, close some locations earlier, citing staffing shortage | CNN business. CNN. http://bit.ly/3RpgS2F. Published January 27, 2023. Accessed February 2, 2023. Keagy J. American Pharmacists Association on move to cut pharmacy hours. American Pharmacists Association. http://bit.ly/3JB0v0Q. Published January 30, 2023. Accessed February 2, 2023. Paxlovid, Lagevrio prescriptions no longer need a positive COVID-19 test. Becker's Hospital Review. http://bit.ly/3DC3Jh3. Published February 1, 2023. Accessed February 2, 2023. Fact sheet for healthcare providers: emergency use authorization for Paxlovid. New York, NY: Pfizer. https://bit.ly/3RvXNvO. Revised February 1, 2023. Accessed February 2, 2023. Fact sheet for healthcare providers: emergency use authorization for Lagevrio (molnupiravir) capsules). Rahway, NJ: Merck & Co. https://bit.ly/3HsLo72. Revised February 1, 2023. Accessed February 2, 2023. Bulloch M. FDA Advisory Committee vote to simplify covid-19 regimen. Pharmacy Times. http://bit.ly/3jweY3t. Published February 1, 2023. Accessed February 2, 2023. O'Mary L. Bacterial outbreak linked to EzriCare eyedrops: CDC. Medscape. http://bit.ly/3l3tOz9. Published February 1, 2023. Accessed February 2, 2023. Update: Multistate Cluster of VIM- and GES-producing Carbapenem resistant Pseudomonas aeruginosa associated with Artificial Tears. https://bit.ly/3DDHrey. Published January 20, 2023. Accessed February 2, 2023. Center for Drug Evaluation and Research. Novel drug approvals for 2023. U.S. Food and Drug Administration. http://bit.ly/3wO6ckC. Accessed February 2, 2023. Pagliarulo N. FDA approves cancer drugs from Lilly, Menarini. BioPharma Dive. http://bit.ly/3DEgnfc. Published January 30, 2023. Accessed February 2, 2023. FDA approves first oral treatment for anemia caused by chronic kidney disease for adults on dialysis. U.S. Food and Drug Administration. http://bit.ly/3RsL64E. Accessed February 2, 2023. FTC enforcement action to Bar Goodrx from sharing consumers' sensitive health info for advertising. Federal Trade Commission. http://bit.ly/3l50F6C. Published February 1, 2023. Accessed February 2, 2023.

Have you been wanting to make the culture at your organization more inclusive and not just in a vertical like DEI, but everywhere throughout the company? Today's guest is Simone Sloan, Rph, MBA, (She/Her), Founder and CEO of Your Choice Coach and is an accomplished business strategist, executive coach, and DEI consultant. Simone has held senior roles at Fortune 500 companies across marketing, communications, medical affairs, sales, and global business strategy. Her tenure includes successfully launching and leading products and services, implementing programs for key stakeholders across the globe, and developing and training sales, medical, and technical teams. Simone's mantra is “Voice, Power, Confidence.” As an emotional intelligence executive coach, she changes the way leaders, and their businesses engage their employees and clients. Simone emphasizes the human element with a focus on diversity and inclusion. She is a keynote speaker and has been featured as a thought leader in articles for Huffington Post, Forbes, and Pharmacy Times. She is an active member of the Tri-State Diversity Council and advocate for women, LGBTQI, BIPOC, people with disabilities, and cross-generations. Take a listen to HerCsuite™ Founder and Host Natalie Benamou, MBA (She/Her) and Simone Sloan, Rph, MBA (She/Her) as they explore The Power of Culture on DEI. Three Ways Organizations Can Integrate DEI Into Their Culture: Leverage ERGs Across The Organization "This is where the conscious intentionality around inclusion has to take place, in terms of the mindset, but also doing the work necessary to move the needle, which means a line item and understanding the resources necessary and the dedication around it. Organizations need sponsors and senior leaders to have an accountability to these programs so that way they too feel connected, are invested. It means tying that to their annual bonus, or even from their compensation as part of that."- Simone Sloan, Rph, MBA (She/Her) Find out more about Simone Sloan, HerCsuite™ Member and Speaker by joining us at our upcoming DEI Cross Organization Council Programs. Sign Up Here: HerCsuite™ Radio is sponsored by our Turnkey Speaker Programs. Schedule a call to learn more. Find Simone Sloan on LinkedIn | Your Choice Coach Thank you, Simone, for this interview, for being a featured speaker and valued member of HerCsuite™ Member Community! Special thanks to HerCsuite™ member and speaker Tosca DiMatteo! Natalie Benamou on LinkedIn | HerCsuite™ LinkedIn

Have you been wanting to make the culture at your organization more inclusive and not just in a vertical like DEI, but everywhere throughout the company? Today's guest is Simone Sloan, Rph, MBA, (She/Her), Founder and CEO of Your Choice Coach and is an accomplished business strategist, executive coach, and DEI consultant. Simone has held senior roles at Fortune 500 companies across marketing, communications, medical affairs, sales, and global business strategy. Her tenure includes successfully launching and leading products and services, implementing programs for key stakeholders across the globe, and developing and training sales, medical, and technical teams. Simone's mantra is “Voice, Power, Confidence.” As an emotional intelligence executive coach, she changes the way leaders, and their businesses engage their employees and clients. Simone emphasizes the human element with a focus on diversity and inclusion. She is a keynote speaker and has been featured as a thought leader in articles for Huffington Post, Forbes, and Pharmacy Times. She is an active member of the Tri-State Diversity Council and advocate for women, LGBTQI, BIPOC, people with disabilities, and cross-generations.  Take a listen to HerCsuite™ Founder and Host Natalie Benamou, MBA (She/Her) and Simone Sloan, Rph, MBA (She/Her) as they explore The Power of Culture on DEI. Three Ways Organizations Can Integrate DEI Into Their Culture: Know your values and really understand what they are and what they mean to you. Listen to the employees because they're on the ground, they're hearing and feeling the culture both virtually and physically in the office. Being flexible in the workplace is giving talent who have invisible disabilities new opportunities. Leverage ERGs Across The Organization Create a sense of community in a global format Spotlight people, functionalities, and the work they are doing Connect employees to the purpose, to the organization and why they're doing what they're doing Find ways to be authentic and connect people together. "This is where the conscious intentionality around inclusion has to take place, in terms of the mindset, but also doing the work necessary to move the needle, which means a line item and understanding the resources necessary and the dedication around it.  Organizations need sponsors and senior leaders to have an accountability to these programs so that way they too feel connected, are invested. It means tying that to their annual bonus, or even from their compensation as part of that."- Simone Sloan, Rph, MBA (She/Her) Find out more about Simone Sloan, HerCsuite™ Member and Speaker by joining us at our upcoming DEI Cross Organization Council Programs. Sign Up Here:  HerCsuite™ Radio is sponsored by our Turnkey Speaker Programs. Schedule a call to learn more. Find Simone Sloan on LinkedIn | Your Choice Coach Thank you, Simone, for this interview, for being a featured speaker and valued member of HerCsuite™ Member Community!  Special thanks to HerCsuite™ member and speaker Tosca DiMatteo! Natalie Benamou on LinkedIn | HerCsuite™ LinkedIn

Thanks to members of Phi Delta Chi's Delta Beta Chapter for creating this episode - Angelica Okinda, Nihitha Nukala, Shannyn Gilchrist-Oates, Hunter Kieltyka, Sydney Thompson, Dylan J. McNutt, Kristopher S. Ingram, Rebecca Nelson, and Emmanuel Rodivera! This week on Pharm5: Glaspie v. NABP Chlorthalidone not superior to HCTZ Krazati (adagrasib) FDA approval ASHP reports 20 states prescribing OCP Federal COVID-19 vaccine funding ends Connect with us! Listen to our podcast: Pharm5 Follow us on Twitter: @LizHearnPharmD References: Ludens ZD, Glaspie E. In the United States District Court for the Northern District of Illinois. Class Action. https://bit.ly/3V7VhM5. Published November 19, 2022. Accessed December 15, 2022. @NABP. As you may have heard, 220 candidates who took the NAPLEX between July 30th and October 26th received incorrect exam results. https://bit.ly/3UXHfN3. Posted November 10, 2022. Accessed December 15, 2022. Ishani A, Leatherman SM, Woods P, et al. Design of a pragmatic clinical trial embedded in the Electronic Health Record: The VA's diuretic comparison project. Contemporary Clinical Trials. 2022;116:106754. doi:10.1016/j.cct.2022.106754 Flack JM, Sica DA, Nesbitt S. Chlorthalidone versus hydrochlorothiazide as the preferred diuretic. Hypertension. 2011;57(4):665-666. doi:10.1161/hypertensionaha.110.164566 Ishani A, Cushman WC, Leatherman SM, Lew RA, et al. Chlorthalidone vs. Hydrochlorothiazide for Hypertension–Cardiovascular Events. 10.1056/NEJMoa2212270. FDA grants accelerated approval to Adagrasib for Kras-G12C-mutated NSCLC. Pharmacy Times. https://bit.ly/3YvCRI8. Published December 13, 2022. Accessed December 15, 2022. Pharmacists can now prescribe hormonal birth control in 20 states. https://bit.ly/3HGMYUI. Published December 5, 2022. Accessed December 15, 2022. Contraception. Centers for Disease Control and Prevention. https://bit.ly/3BGTRl7. Published November 1, 2022. Accessed December 15, 2022. Pharmacist prescribing: Hormonal contraceptives. https://bit.ly/3hqbHSx. Published December 6, 2022. Accessed December 15, 2022. Stephenson J. US COVID-19 Vaccine Costs Expected to Soar if Funding for Federal Program Ends. JAMA Health Forum. 2022;3(12):e225376. doi:10.1001/jamahealthforum.2022.5376 Artiga S, Tolbert J, Kates J, Rudowitz R. Implications of the lapse in federal covid-19 funding on access to covid-19 testing, treatment, and vaccines. KFF. bit.ly/3FWDLpM. Published March 28, 2022. Accessed December 15, 2022.

This week on Pharm5: Imjudo (tremelimumab) FDA approved Tecvayli (teclistamab-cqyv) FDA approved Cancer incidence up, mortality down Pharmacies administered >50% of COVID vaccines AGA Obesity Treatment Guidelines Connect with us! Listen to our podcast: Pharm5 Follow us on Twitter: @LizHearnPharmD References: Imjudo (tremelimumab) in combination with Imfinzi approved in the US for patients with unresectable liver cancer. AstraZeneca. https://bit.ly/3NevJKX. Published October 24, 2022. Accessed October 27, 2022. Abou-Alfa GK, Lau G, Kudo M, et al. Tremelimumab Plus durvalumab in unresectable hepatocellular carcinoma. NEJM Evidence. 2022;1(8). doi:10.1056/evidoa2100070 Center for Drug Evaluation and Research. FDA approves teclistamab-cqyv for relapsed or refractory multiple myeloma. U.S. Food and Drug Administration. https://bit.ly/3zqMixF. Accessed October 27, 2022. Cronin KA, Scott S, Firth AU, et al. Annual report to the nation on the status of cancer, part 1: National cancer statistics. Cancer. October 2022. doi:10.1002/cncr.34479 Hunter E. Overall cancer death rates have declined, but rates among racial/ethnic minorities have not followed suit. Pharmacy Times. https://bit.ly/3gPg4G0. Published October 27, 2022. Accessed October 27, 2022. Grabenstein JD. Essential services: Quantifying the contributions of America's pharmacists in COVID-19 clinical interventions. Journal of the American Pharmacists Association. 2022. doi:10.1016/j.japh.2022.08.010 @JAPhAJournal. IN PRESS: Pharmacists delivered over 350 million clinical interventions during COVID pandemic. #TwitteRx #pharmacists #COVID19. Posted October 25, 2022. Accessed October 27, 2022. https://bit.ly/3U1xn4N. Grunvald E, Shah R, Hernaez R, et al. AGA clinical practice guideline on pharmacological interventions for adults with obesity. Gastroenterology. 2022;163(5):1198-1225. doi:10.1053/j.gastro.2022.08.045

Episode 114: Diabetes care updateYvette presents updates from ADA on diabetes care regarding SGLT-2 inhibitors, GLP-1 receptor agonists, and finerenone. Written by Yvette Singh, MSIV, American University of the Caribbean. Comments and text edition by Hector Arreaza, MD. You are listening to Rio Bravo qWeek Podcast, your weekly dose of knowledge brought to you by the Rio Bravo Family Medicine Residency Program from Bakersfield, California, a UCLA-affiliated program sponsored by Clinica Sierra Vista, Let Us Be Your Healthcare Home. This podcast was created for educational purposes only. Visit your primary care provider for additional medical advice.The American Diabetes Association (ADA) released revisions in May 2022; specifically regarding sodium-glucose cotransporter-2 (SGLT-2) inhibitors, glucagon-like peptide-1 receptor agonists (GLP-1 RA), and finerenone for cardiovascular and renal comorbidities. What are SGLT2 inhibitors and GLP-1 receptor agonists?SGLT2 inhibitor class of oral antidiabetic drugs, including empagliflozin, canagliflozin, dapagliflozin, and more. They increase the excretion of glucose and sodium in the urine by inhibiting SGLT2 in the kidney, thus lowering blood glucose levels. In other words, it has a glucoretic effect. GLP-1 receptor agonists are a class of non-insulin drugs, including exenatide, liraglutide, semaglutide, and more. They mimic the intestinal hormone incretin and bind to its receptor, which slows the rate at which foods leave the stomach, controls appetite, and regulates insulin and glucagon secretion.What is the NEW use of SGLT-2 Inhibitors and GLP-1 RA in treatment?Traditional glucocentric approaches recommend initial medications such as metformin for most adults with type 2 diabetes, leaving SGLT-2 inhibitors and GLP-1 receptor agonists as alternative options mainly for patients with high risk for atherosclerotic cardiovascular disease in whom additional glucose lowering was needed after metformin treatment. Current guidelines now recommend these agents (SGLT-2 inhibitors and GLP-1 RA) for any T2DM patient with current or high-risk for ASCVD, chronic kidney disease (CKD), or heart failure (HF). This guideline stands regardless of the need for additional glucose lowering and/or metformin use. This has now changed through trials, demonstrating that cardiovascular disease and chronic kidney disease benefits independent of a medication's glucose-lowering potential.HbA1c has long been used to guide clinical decision-making about type 2 diabetes. However, systematic reviews have revealed minimal benefits in the normalization of HbA1c.Moreover, the cardiovascular and kidney protection of SGLT-2 inhibitors and GLP-1 receptor agonists are unrelated to their impact on HbA1c. Double-blinded randomized clinical trials showed that SGLT-2 inhibitors reduced the risk of cardiovascular death and hospitalization for heart failure in patients with or without diabetes. Therefore, cardiovascular and kidney risk, rather than HbA1c, constitutes a possible indication for the two medication classes. If patients with ASCVD remain above goal A1C despite the addition of an SGLT-2 inhibitor or GLP-1 RA, then adding the agent the patient is not currently on out of the two is recommended before dipeptidyl peptidase-4 aka (DPP-4) inhibitors, basal insulin, or sulfonylureas because the combined use of an SGLT-2 inhibitor and GLP-1 RA can produce an additive risk reduction for cardiovascular and renal adverse events.What is Finerenone, and how does it help with diabetes? Finerenone (Kerendia®) selectively blocks sodium reabsorption and overactivation of mineralocorticoid receptors within epithelial and non-epithelial tissues. This, in turn, reduces fibrosis and inflammation of both the kidneys and blood vasculature.Finerenone use for patients with advanced CKD, i.e., moderately elevated albuminuria, eGFR of 25- 60 mL/min, and diabetic retinopathy, is encouraged for nephroprotection. However, Patients with less-advanced CKD, i.e., stages 1-2, do not receive any benefit. Regardless of the severity of CKD, SGLT-2 inhibitors remain first-line therapy.Although Finerenone improves cardiovascular outcomes and reduces CKD progression for patients, it is still unknown if there are any additive cardioprotective effects if used with SGLT2 inhibitors and/or GLP-1 receptor agonists.Some Closing Pearls: The use of SGLT2 inhibitors in patients with eGFR > 25 decreased from 30 previously.If the A1c goal is not being met, combination therapy of insulin with a GLP receptor agonist can be considered, as this combination treatment has been shown to increase the efficacy and duration of insulin.Overall, this new change could be very beneficial if accepted internationally. Though understandably, there could be some limitations to this guideline given the availability and cost of these medications, as well as their contraindication of use in specific populations such as pregnancy, ages >65 with concurrent risk factors for hypoglycemia or dehydration, and those with history of acute pancreatitis. ____________________________Conclusion: Now we conclude our episode number 114 “Diabetes care update.” Yvette explained that the ADA now recommends the use of SGLT2 inhibitors and GLP-1 agonists in any patient with type 2 diabetes with current or at high risk for cardiovascular disease, chronic kidney disease, or heart failure. Primary care physicians should become familiar with the dosing, cautions, side effects, and contraindications of these meds. Also, a newer medication for CKD in diabetes was mentioned: Finerenone. Diabetes treatment continues to evolve, and we hope this information is useful for you. This week we thank Hector Arreaza, Yvette Singh, and Fiona Axelsson. Audio edition by Adrianne Silva.Even without trying, every night you go to bed a little wiser. Thanks for listening to Rio Bravo qWeek Podcast. We want to hear from you, send us an email at RioBravoqWeek@clinicasierravista.org, or visit our website riobravofmrp.org/qweek. See you next week! _____________________________Lacanlale, Jana K et al. “Notable Revisions in Diabetes Treatment According to ADA Guidelines.” Pharmacy Times, 26 Mar. 2021, https://www.pharmacytimes.com/view/notable-revisions-in-diabetes-treatment-according-to-ada-guidelines.Li, Sheyu, et al. “SGLT-2 inhibitors or GLP-1 receptor agonists for adults with type 2 diabetes: a clinical practice guideline.” British Medical Journal 2021; 373:n1091. doi:10.1136/BMJ.n1091Royalty-free music used for this episode: BUrn Flow by Gushito, downloaded on September 22, 2022, from https://www.videvo.net/royalty-free-music-track/burn-flow/1008877/ 

Jill Murphy from Pharmacy Times® spoke with Public Health Matters host Dr. Christina Madison, On the Shelf host Dr. Joanna Lewis, and Dr. Brooke Griffin about all things pharmacy, including the importance of Women Pharmacist Day and what they hope to see in the future of pharmacy. Enjoy!

If you're a woman, especially if you're a mother, I want you to listen to this episode again because Dr. Jennifer Bourgeois will pour her heart and soul into you. There will be a lot of parallels between her story and yours. And at the conclusion of this episode, I want each of you to do something. So, functional medicine expert Dr. Jennifer Bourgeois is from STORRIE Institute™. She practices integrative medicine. She has more than 15 years of expertise in the health and wellness sector as a clinical pharmacist. She has two children. And this is so amazing, she has recently joined the American Institute of Stress as a fellow. Again, she realized the power of what is possible since she was a clinician going through her own health transformation with functional medicine. She also wanted to study more and obtain this further training in order to become a clinician and practitioner in this functional medicine arena.   Listen to this episode to find out why it's crucial!   “You are worthy to invest in yourself, you are worthy, and you're also capable of changing your life again.”    Keynotes You cannot correct an emotional wound. To get to the root of what's actually happening. Impact clients in this holistic approach. Step forward to learn how to become the best version of yourself. Allow yourself to learn. Dr. Jennifer Bourgeois is a Functional Medicine Specialist™ from  STORRIE™ Institute, Integrative Health Practitioner, Bestselling Author (Creating The Functional Medicine Revolution) and Clinical Pharmacist with over 15 years of experience in the health and wellness industry. She is a Fellow at American Institute of Stress. After experiencing her own health transformation using functional medicine, she decided to gain additional training to become a certified practitioner herself.    Dr. Jennifer is the Founder and CEO of Well & Free, LLC and the founder of the STRESSED MOM™ Transformation. Through her practice and programs, she is able to help women restore health and discover balance with a science meets soul approach.   SingleCare recognized Dr. Jennifer as the Best Pharmacist of 2021 for her commitment to service and excellence in the profession. She has been featured in Pharmacy Times, Drug Topics, Pharmacist Moms Blog, and numerous podcasts.   In addition to her professional roles, Dr. Jennifer is the founder of a non-profit, A New View, that recycles and repurposes used eyeglasses. She founded her non-profit in honor of her oldest daughter, who was diagnosed with strabismus and other vision impairments at the age of one. A New View has given over 3,000 eyeglasses to people in need.   Dr. Jennifer is a devoted wife and mother who is passionate about wellness and her faith. She loves traveling, volunteering, and the freedom that comes along with entrepreneurship.    As a high-achieving working mom herself, she knows first-hand how essential emotional, mental, physical, and spiritual wellbeing are for living a vibrant life. Dr. Jennifer is on a mission to serve busy and over-scheduled moms to help create balance through a body, mind, and soul care approach.   Connect with Dr. Jennifer Bourgeois    https://www.drjenbourgeois.com/  Email: drjenbourgeois@gmail.com  IG: https://www.instagram.com/drjenbourgeois/  LI: https://www.linkedin.com/in/drjenbourgeois/  FB: https://www.facebook.com/jennifer.bourgeois.35    Connect with Dr. Christine Manukyan  www.drchristinemanukyan.com  Email: drchristine@storrie.co  LI https://www.linkedin.com/in/dr-christine-manukyan/ IG https://www.instagram.com/dr.christine.manukyan/ FB https://www.facebook.com/drchristinemanukyan   Connect with STORRIE Institute™  www.storrieinstitute.com  Email: info@storrieinstitute.com  IG: https://www.instagram.com/storrie.institute/  FB: https://www.facebook.com/Storrie-Institute-104893301977544  Join our Facebook community  https://www.facebook.com/groups/functionalmedicinebusinesscoaching 

During our conversation, we talk about putting the “care” back in healthcare and becoming more culturally competent.  The goal is for patients to achieve better health outcomes because they trust what we [as pharmacists] are saying.   Thank you for listening to episode 176 of The Pharmacist's Voice ® Podcast! To read the full show notes, visit https://www.thepharmacistsvoice.com.  Click on the podcast tab, and search for episode 176. Bio:  Simone Sloan, Positive Disruptor RPh, MBAAs Founder and CEO of Your Choice Coach, Simone is an accomplished business strategist, executive coach, and DEI consultant. She has held senior roles at Fortune 500 companies across marketing, communications, medical affairs, sales, and global business strategy. Her tenure includes successfully launching and leading products and services, implementing programs for key stakeholders across the globe, and developing and training sales, medical, and technical teams.    Simone's mantra is “Voice, Power, Confidence.” As an emotional intelligence executive coach, she changes the way leaders and their businesses engage their employees and clients. Simone emphasizes the human element with a focus on diversity and inclusion.  Simone is a keynote speaker and has been featured as a thought leader in articles for Huffington Post, Forbes, and Pharmacy Times. She is an active member of the Tri-State Diversity Council and advocate for women, 2LGBTQAI++, BIPOC, people with disabilities, and cross-generations.  Simone holds a BS in Pharmacy and an MBA from Howard University. She is co-author of the book: Achieving Results, 30 Days to Courage, and Leadership without Borders, and is certified in DISC, Emotional Intelligence (EQI) 2.0, IDI, Cultural Competence, Cultural Intelligence (CQI), Culture- Values, Block Chain, Behavior Design, and is also accredited through the International Coaching Federation.

This week on Pharm5: Rapid-acting Auvelity (bupropion/dextromethorphan) for MDD USPSTF's updated statin recommendations Post flu vaccination hyperglycemia in type 2 diabetes Twice annual HIV treatment lenacapavir approved in Europe; awaiting FDA approval Student loan forgiveness Connect with us! Listen to our podcast: Pharm5 Watch us on TikTok: @LizHearnPharmD Follow us on Twitter: @LizHearnPharmD References: Saro Arakelians PD. Daily medication pearl: Dextromethorphan and bupropion (Auvelity). Pharmacy Times. https://bit.ly/3QPIRY8. Published August 24, 2022. Accessed August 24, 2022. Auvelity (dextromethorphan and bupropion). Package insert. Axsome Therapeutics, Inc; 2022. @DrWestling15. “FDA just approved Auvelity (Dextromethorphan-Bupropion) for Major Depressive Disorder! What should a pharmacist know about this?” https://bit.ly/3R4WKkX. Published August 22, 2022. Accessed August 24, 2022. Mangione CM, Barry MJ, Nicholson WK, et al. Statin use for the primary prevention of cardiovascular disease in adults. JAMA. 2022;328(8):746. doi:10.1001/jama.2022.13044. Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;140(11). doi:10.1161/cir.0000000000000678 Blood sugars higher for flu vaccine recipients with diabetes. U.S. Pharmacist – The Leading Journal in Pharmacy. https://bit.ly/3PKbDrH. Published August 24, 2022. Accessed August 24, 2022. Hulsizer AL, Witte AP, Attridge RL, Urteaga EM. Hyperglycemia Post-Influenza vaccine in patients with diabetes. Annals of Pharmacotherapy. June 2022:106002802210981. doi:10.1177/10600280221098101 Kansteiner F. Gilead HIV prospect escapes FDA hold after glass compatibility glitch triggered regulatory setbacks. Fierce Pharma. https://bit.ly/3R3h3yY. Published May 17, 2022. Accessed August 24, 2022. Gilead announces first global regulatory approval of Sunlenca® (Lenacapavir), the only twice-yearly HIV treatment option. Gilead Announces First Global Regulatory Approval of Sunlenca® (Lenacapavir), the Only Twice-Yearly HIV Treatment Option. https://bit.ly/3dXZd2t. Accessed August 24, 2022. Duster C. How to qualify for Biden's new student loan forgiveness plan. CNN Politics. https://cnn.it/3ALjKjF. Published Wednesday August 24, 2022. Accessed August 24, 2022. Occupational Employment and Wages, May 2021 - Pharmacists. U.S. Bureau of Labor Statistics. https://bit.ly/3PObHXm. Published March 31, 2022. Accessed August 24, 2022. Smoot C. What is the average pharmacy school debt in 2022? SuperMoney. https://bit.ly/3PHqZNK. Published April 26, 2022. Accessed August 24, 2022.

The recently signed gun law, S. 2938: Bipartisan Safer Communities Act, contained a surprise dingleberry postponing a regulation designed to save seniors money on their pharmaceutical drugs by prohibiting kickbacks to an industry few have heard of: Pharmacy Benefit Managers (PBMs). This little-known but extremely powerful industry deserves much of the blame for ever rising prescription drugs costs in the United States. In this episode, Jen gives you the scoop on PBMs and how they make their money at the expense of Americans who are most dependent on medications. Please Support Congressional Dish – Quick Links Contribute monthly or a lump sum via PayPal Support Congressional Dish via Patreon (donations per episode) Send Zelle payments to: Donation@congressionaldish.com Send Venmo payments to: @Jennifer-Briney Send Cash App payments to: $CongressionalDish or Donation@congressionaldish.com Use your bank's online bill pay function to mail contributions to: 5753 Hwy 85 North, Number 4576, Crestview, FL 32536. Please make checks payable to Congressional Dish Thank you for supporting truly independent media! View the shownotes on our website at https://congressionaldish.com/cd255-pharmacy-benefit-managers-pbms We're Not Wrong Berlin Meetup Contact Justin at WereNotWrongPod@gmail.com Background Sources Recommended Congressional Dish Episodes CD134: The EpiPen Hearing US Healthcare Landscape Jessi Jezewska Stevens. Apr 23, 2020. “A Brief History of the Great American Healthcare Scam.” Bookforum. Tanza Loudenback. Mar 7, 2019. “The average cost of healthcare in 21 different countries.” Insider. Chuck Grassley and Ron Wyden. 2019. “Insulin: Examining the Factors Driving the Rising Cost of a Century Old Drug [Staff Report].” U.S. Senate Finance Committee. “Health Insurance Coverage of the Total Population.” Kaiser Family Foundation. Sara R. Collins and David C. Radley. Dec 7, 2018. “The Cost of Employer Insurance Is a Growing Burden for Middle-Income Families.” The Commonwealth Fund. PBMs What are PBMs? JC Scott. Jun 30, 2022. “Drug manufacturers are root cause of high drug costs; PBMs drive costs down.” The Hill. Zach Freed. Jun 22, 2022. “The Pharmacy Benefit Mafia: The Secret Health Care Monopolies Jacking Up Drug Prices and Abusing Patients and Pharmacists.” American Economic Liberties Project. Adam J. Fein. Jun 22, 2021. “The Top Pharmacy Benefit Managers of 2020: Vertical Integration Drives Consolidation (rerun).” Drug Channels. “Flash finding: How drug money from sick people really works.” Nov 11, 2021. 46brooklyn. Adam J. Fein. Feb 3, 2019. “Don't Blame Drug Prices on ‘Big Pharma.'” The Wall Street Journal. How PBMs Make Money “DIR Fees.” National Association of Chain Drug Stores. “How PBMs Make Money: PBM Practices & Profits.” RxSafe. True North Political Solutions. Oct 25, 2017. “White Paper: DIR Fees Simply Explained.” Pharmacy Times. ACA “Vertical Integration” Loophole Peter High. Jul 8, 2019. “A View From Inside Cigna's $67 Billion Acquisition Of Express Scripts.” Forbes. Angelica LaVito. Nov 28, 2018. “CVS creates new health-care giant as $69 billion merger with Aetna officially closes.” CNBC. David Dayen. Oct 12, 2018. “Why the Aetna and CVS Merger Is So Dangerous.” The American Prospect. Jeff Byers. April 12, 2018. “Optum a step ahead in vertical integration frenzy.” Healthcare Dive. Graph: Optum opens up wider market for UnitedHealth Group Graph: Optum's pharmacy business contributes the majority of its revenue Susan Morse. May 10, 2017. “Secret weapon: UnitedHealth's Optum business is laying waste to old notions about how payers make money.” Healthcare Finance. Lobbying “Client Profile: Pharmaceutical Care Management Assn.” Open Secrets. The Demise of Independent Pharmacies Christine Blank. Oct 17, 2019. “Independents Prepare to Close Up Shop.” Drug Topics. Paulina Firozi. Aug 23, 2018. “The Health 202: Here's why rural independent pharmacies are closing their doors.” The Washington Post. What Is a Formulary? Ana Gascon Ivey. May 19, 2020. “A Guide to Medication Formularies.” GoodRx. Previous Delays in Rebate Regulation Paige Minemyer. Jan 29, 2021. “In a win for PBMs, Biden administration delays rebate rule.” Fierce Healthcare. Paige Minemyer. Jan 12, 2021. “PCMA sues Trump administration over rebate rule.” Fierce Healthcare. “Incorporating the Effects of the Proposed Rule on Safe Harbors for Pharmaceutical Rebates in CBO's Budget Projections—Supplemental Material for Updated Budget Projections: 2019 to 2029.” May 2019. Congressional Budget Office. The Gun Law Passage Process Office of the Clerk. May 18, 2022. “Roll Call 212 | Bill Number: S. 2938.” U.S. House of Representatives. Tampa Bay Times Editorial Board. May 12, 2022. “Republican lawmakers should be ashamed for failing to honor Justice Joseph Hatchett.” Miami Herald. Annie Karni. Apr 12, 2022. “House G.O.P., Banding Together, Kills Bid to Honor Pioneering Black Judge.” The New York Times. Background on Most Important Provisions Mary Katherine Wildeman. May 26, 2022. “Data show most school shootings carried out by young adults, teens.” CT Insider. Jeffrey Pierre. May 26, 2022. “Experts say we can prevent school shootings. Here's what the research says.” NPR. The Dingleberry Erik Sherman. Jun 30, 2022. “Gun Safety Bill Extends Drug Middlemen Protection From Anti-Kickback Measure.” Forbes. Molly Rutherford. Jun 28, 2022. “Gun legislation provision puts drug supply chain profits over patients.” The Hill. Marty Schladen. Jun 22, 2022. “Deep inside the gun bill: a break for prescription drug middlemen.” Iowa Capital Dispatch. Poland Train Station Taylor Popielarz, Maureen McManus and Justin Tasolides. Mar 25, 2022. “‘The help given is remarkable': Inside the Poland train station that's become a hub for Ukrainian refugees.” Spectrum News NY1. The Law and the Regulation S. 2938: Bipartisan Safer Communities Act Senate Vote: 65-33 (All Nos GOP) House Vote: 234-193 (All Nos GOP) Jen's Highlighted PDF of S. 2938: Bipartisan Safer Communities Act Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees U.S. Health and Human Services Department November 30, 2020 Audio Sources The State of Competition in the Pharmacy Benefits Manager and Pharmacy Marketplaces November 17, 2015 House Committee on the Judiciary Witnesses: Bradley J. Arthur, R.Ph., Owner, Black Rock Pharmacy David Balto, Law Offices of David A. Balto PLLC Amy Bricker, R.Ph. Vice President of Retail Contracting & Strategy, Express Scripts Natalie A. Pons, Senior Vice President and Assistant General Counsel, CVS Health Clips 53:48 Bradley Arthur: The Big Three PBMs control almost 80% of the entire market and these PBMs have the upper hand both in negotiating the contract with the payer, as well as strongly influencing the actual plan design itself. The PBM industry typically states that they can use their economic power to harness enhanced market efficiencies, but for whom? However, the staggering annual revenues that continue to grow each year of the big three suggests that these efficiencies are going directly to their corporations' bottom lines. Small community pharmacies like mine are faced on a daily basis with the impact of the PBMs' disproportionate market power. Community pharmacies routinely must agree to take-it-or-leave-it contracts from the PBMs just to continue to serve our long-standing patients. As if that weren't enough, the PBMs also directly set the reimbursement rates for pharmacies, the very same pharmacies that stand in direct competition of some of these PBM-owned mail-order and specialty pharmacies. Therefore, it comes as no surprise that the PBMs present employer and government payers with carefully tailored suggested plans designs that steer beneficiaries to these PBM-owned entities. Drug Pricing in America: A Prescription for Change, Part I January 29, 2019 Senate Committee on Finance Witnesses: Kathy Sego, Mother of a Child with Insulin-Dependent Diabetes Douglas Holtz-Eakin, Ph.D., President, American Action Forum Mark E. Miller, Ph.D., Vice President of Health Care, Laura and John Arnold Foundation Peter B. Bach, MD, MAPP, Director, Memorial Sloan Kettering Center for Health Policy and Outcomes Clips 1:57:30 Sen. John Cornyn (R - TX): Can anybody on the panel explain to me why we have a general prohibition against kickbacks — they call them rebates — under the Social Security Act, but we nevertheless allow it for prescription drug pricing? What's the sound public policy reason for excluding prescription drug pricing from the anti-kickback rule under federal law? Douglas Holtz-Eakin: I can't explain that and won't pretend to. [laughter] Sen. Cornyn: I thought I was the only one who didn't understand the wisdom of that. Well, it's not a transparent arrangement and it does produce upward pressure on drug prices. And obviously, the negotiations between the PBM and the pharma in terms of what the net cost is, is not transparent, nor is it delivered to the consumer. Is it Dr. Miller? Dr. Bach? Peter Bach: It's delivered to the consumer indirectly through the reduction of the total cost of the benefit, but it is not delivered to the actual consumer using the drug, and that is a disassociation, that is a problem. Because it essentially reverses the structure of insurance. Lowering the total costs are people who use it the least, and raising the costs are people who use it the most, relative to if you allowed the rebate to be used at the point of sale, including all discounts. 1:59:49 Douglas Holtz-Eakin: If we had the negotiation be about the upfront price, so instead of a high list price and a rebate, you just negotiate a lower price, that would be the price that Ms. Sego would pay and insurance companies would look at that and say, okay, she's not paying as much as she used to, we're going to have to make up that money somewhere else and they might raise premiums. That means that people who don't have extreme insulin drug costs would pay a little bit more in a premium every month, and people who have extremely devastating medical conditions and high health care costs would get less costs. That's exactly what insurance is supposed to do. And so the rebate system is more than giving strange incentives on pricing. It's undercutting the purpose of insurance in general. Drug Pricing in America: A Prescription for Change, Part II February 26, 2019 Senate Committee on Finance Witnesses: Richard A. Gonzalez, Chairman and Chief Executive Officer, AbbVie Inc. Pascal Soriot, Executive Director and Chief Executive Officer, AstraZeneca Giovanni Caforio, M.D., Chairman of the Board and Chief Executive Officer, Bristol-Myers Squibb Co. Jennifer Taubert, Executive Vice President, Worldwide Chairman, Janssen Pharmaceuticals, Johnson & Johnson Kenneth C. Frazier, Chairman and Chief Executive Officer, Merck & Co., Inc. Albert Bourla, DVM, Ph.D., Chief Executive Office, Pfizer Olivier Brandicourt, M.D., Former Chief Executive Officer, Sanofi Clips 1:22:03 Albert Bourla: Adverse incentives that favor higher cost biologics are keeping biosimilars from reaching patients. In many cases, insurance companies declined to include lower cost biosimilars in their formularies because they would risk losing the rebates from covering higher cost medicines. I can't think of a more concerning example of a broken system and we need to do something about it. 1:33:35 Sen. Chuck Grassley (R - IA): So many of you have voiced support for the recent rebate rule proposed by the administration. Should the administration finalized this rule, will you commit to lowering your drug prices? Richard Gonzalez [CEO, AbbVie]: Mr. Chairman, we are supportive of the rule. We'd like to see it in its final form, obviously, to make a final decision, but we are supportive of taking the discount to the patient at the point of sale. Sen Grassley: Okay. AstraZeneca? **Pascal Soriot [CEO, AstraZeneca]**The same for us Senator, I would go one step further: if the rebates were removed from the commercial sector as well, we will definitely reduce our list prices. Sen Grassley: Okay. And Bristol? Giovanni Caforio [CEO, Bristol-Myers Squibb]: We have the same positions. Sen Grassley: Okay. Johnson and Johnson? Jennifer Taubert [EVP, J&J]: Yes, we're supportive, and that definitely would be my goal. We would just need to see the final legislation, provided that there aren't additional fees that are added into the system to compensate for the rebates. Sen Grassley: Merck? **Kenneth C. Frazier: I would expect that our prices would go down if we change the system. Again, on the commercial side as well as the Medicare side. Sen Grassley: Okay, Pfizer? Albert Bourla [CEO, Pfizer]: It is a very clear intention that we will not keep a single dollar from these rebates. We will try to move every single penny to the patients and we think if this goes also to the commercial plants that will be even better for more patients. Sen Grassley: Okay. Sanofi? Olivier Brandicourt [Former CEO, Sanofi]: Lowering list price has to be linked to better access and affordability at the counter for the patients. 1:35:20 Sen. Ron Wyden (D - OR): Is it correct that your company, and nobody else, sets the starting price for all drugs sold by Pfizer? Yes or no? Albert Bourla: It is a negotiation with PBMs and they are very powerful. Sen. Wyden: But you still get to set the list price? Albert Bourla: Yes, but we set this price and the rebate limit(?). 1:35:40 Sen. Ron Wyden (D - OR): Is it correct, when a hypothetical patient, let's call her Mrs. Jones, goes to pay for her drug at the pharmacy counter, her coinsurance is based on the price of the drug you set? Albert Bourla: It is correct in many cases. Sen. Wyden: Okay. I just want you all to know that the number one reason consumers are getting hammered, is because these list prices, which you have the last word with respect to where they are, are unaffordable. And the high prices are tied to what the consumer pays at the pharmacy counter. And all this other stuff you talk about, the rebates and the discounts and the coupons, all this other stuff is window dressing, all of that. And the fact is on Part D, 40% of the drugs don't even have a rebate. So I want it understood, particularly because I've asked you, Mr. Borla, I think you and others in the industry are stonewalling on the key issue, which is actually lowering list prices. And reducing those list prices are the easiest way for American consumers to pay less at the pharmacy counter. 2:12:45 Sen. Thomas Carper (D-DE): First is eliminating rebates to PBMs. That's the first one, eliminating rebates to PBMs. The second is value based arrangements. And the third is increasing transparency industry-wide on how you set your prices. 2:13:20 Richard Gonzalez: We clearly support providing the discount at the patient level, eliminating rebates essentially. 2:14:10 Pascal Soriot: If the rebates, as I said earlier, were to be removed from Part D and the commercial sector, we would actually reduce our list prices. 2:15:10 Giovanni Caforio: I would say that not only do we support all three elements that you mentioned, but I do believe those three elements together with the continued effort to develop a generic and biosimilar market would mean significant change, and would clearly alleviate the concerns that patients have today. 2:14:44 Jennifer Taubert: We are very supportive of all three elements that you outlined 2:15:52 Kenneth Frazier: We too support all three. 2:15:55 Albert Bourla: All three elements are transformational for our industry, will disrupt it. However, we do agree that these are the three things that need to be done and also I believe that will have significant meaningful results if we do. 2:16:10 Olivier Brandicourt: We support the three Senator, but we want to keep in mind at the end of the chain the patient has to benefit, so if rebates are removed it has to be to the benefit of patients. Sen. Thomas Carper (D-DE): Good, thanks. 2:18:10 Albert Bourla: 50% of the American people are in commercial plans and these rebate rules apply to Medicare. If the rules apply to all, definitely the list price will go down. 2:18:30 Albert Bourla: The list price is not irrelevant, it's very relevant for a lot of people because they have to pay list price during the deductible period. However if the rebate rule is applied, then they become irrelevant because the patients will not be paying the list price at the purchase point. 2:19:10 Sen. John Thune (R-SD): How would manufacturers respond if the rebate rule were finalized for government programs? I mean, what does that what does that mean for the commercial market? Albert Bourla: Senator, as I said before, all these proposals that they're discussing, [undistinguishable], eliminating the rebate rule, are transformational and will disrupt the way we do business. I don't know exactly how the system will evolve, and I really don't favor a bifurcated system. I would like to have a transparent single system across both parts. So we need to see how the whole thing will evolve. 2:25:26 Johnny Isakson (R-GA): Who sets the discount and who sets the rebate? 2:26:20 Richard Gonzalez: We negotiate with payers, so managed care and PBMs— Sen. Johnny Isakson (R-GA): You're a supplier though, so you have to go negotiate with the PBMs and those people, is that right? Richard Gonzalez: Correct, and they negotiate aggressively. Sen. Isakson: Is that pretty much true with everybody, that they're the major component between the end retail consumer price and the origin of the product? Richard Gonzalez: Yes, Senator. Sen. Isakson: Well, that seems like that's someplace we ought to focus, because that's where the distorted numbers come in. Johnson & Johnson, Janssen, in your testimony, you talked about your average list price of 8.1%, up, but an average net price change of only 4.6%. So while your gross went up 8.6, your net went down 4.6 In the same pricing period. How does that happen? If you're setting the price, how does it not go up on the bottom? Jennifer Taubert: Yeah, and in fact, in 2018, our net price actually declined 8.6%, so even more than that. The intermediaries in the system are very, very effective negotiators— Sen. Isakson: Tell me who the intermediaries are. Jennifer Taubert: Those would be the PBMs and the insurers. Sen. Isakson: …and the insurance companies? Jennifer Taubert: Right, and they set the formularies for patients. Sen. Isakson: And they're not the same. They're two different people? Jennifer Taubert: Yes, correct. 2:40:45 James Lankford (R-OK): All of you have mentioned the rebate issue has been a problem and that insurance companies and PBMs are very effective negotiators. Part of the challenge of this is, health insurance companies pay their PBM based on the quality of their negotiation skills, cutting a price off the list price. And so if a list price is higher and a rebate is higher, that also gives preference to them. So the difficulty is, as you raise list price, and the rebate gets larger, the insurance company gives that preference, making it harder for biosimilars. Am I tracking this correctly? 2:43:00 Albert Bourla: Here in the US, the penetration of biosimilars is much lower than in other places, but it is disproportional to different parts of the US healthcare system. For example, in open systems, systems where the decision maker it is a PBM, the one biosimilar we have has a market share of 5% in the US. In closed systems, in systems like Kaiser, for example, integrated healthcare systems where the one who decides has the whole cost of the healthcare system in its interest, we have 73%. 5% and 73% for the same product. I agree with what Mr. Fraser said that we need to create incentives, but I would add also that we need to break this rebate trap that creates significant disincentives for providers, and the healthcare system, and insurance companies. 3:19:25 Kenneth Frazier: If you went back a few years ago, when we negotiated to get our drugs on formulary, our goal was to have the lowest copay by patients. Today the goal is to pay into the supply chain the biggest rebate, and so that actually puts the patient at a disadvantage since they're the only ones that are paying a portion of the list price. The list price is actually working against the patient. 3:19:50 Sen. Steve Daines (R-MT): Why do we have a system today? Where you all are setting, I'll just say very, very high list prices, which is the starting point for negotiation. Why? Olivier Brandicourt: Senator, we're trying to get formulary position. With those list prices. High list price, high rebates. It's a preferred position. Unfortunately the preferred position doesn't automatically ensure affordability at the end. Kenneth C. Frazier: Senator, If you bring a product to the market with a low list price in this system, you get punished financially and you get no uptake because everyone in the supply chain makes money as a result of a higher list price. Drug Pricing in America: A Prescription for Change, Part III April 9, 2019 Senate Committee on Finance Witnesses: Steve Miller, MD, Former Executive Vice President and Chief Clinical Officer, Cigna Corporation Derica Rice, Former Executive Vice President and President, CVS Health and CVS Caremark William Fleming, Pharm.D., Segment President, Healthcare Services, Humana Inc. John Prince, Chief Executive Officer, OptumRx Mike Kolar, JD, Interim President & CEO, Senior Vice President and General Counsel, Prime Therapeutics LLC Clips Sen. Ron Wyden (D - OR): Pharmaceutical Benefit Managers first showed up decades ago, back when prescription drugs were being utilized more extensively. The PBMs told the insurance companies, “we're the ones who know drug pricing, we will handle the negotiations for you.” But there is little evidence that the pharmaceutical benefit managers have actually held down the prices in a meaningful way. In fact, most of the evidence shows just the opposite. Pharmaceutical Benefit Managers actually make more money when they pick a higher price drug over a lower price drug. Colleagues, let's remember that all the way through this discussion, benefit managers make more money when they pick a higher price drug over a lower price drug. The logic on this isn't exactly complicated, graduate-level economics. PBM profits are based on taking their slice of the prescription-drug pie. More expensive drugs means there's a bigger pie. When there's a bigger pie, [there are] bigger slices for the pharmaceutical benefit managers. 50:24 Mike Kolar: Rebates and the role they play have been key areas of focus in the drug cost debate. In our view, rebates are a powerful tool to offset high prices, which are set by pharmaceutical companies, and pharmaceutical companies alone. The fact that rebates are not offered on many of the highest cost drugs, and that studies show no correlation between prices and rebates underscore that rebates are a key to mitigating rather than causing high drug prices. We pass rebates through fully to our plans, and we believe our plans should be able to choose how to apply these rebates in ways that best serve their members and market needs by balancing premiums and cost sharing. 56:05 Sen. Chuck Grassley (R-IA): I'd like to talk about consolidation, including the recent integration of PBMs with insurance companies. Last year I wrote to the Justice Department on the issues, it reported that the three largest PBMs who are before us today now covers 71% of Medicaid, Medicare Part D enrollees and 86% of standalone Drug Plan enrollees. 57:45 Derica Rice: This is a highly competitive space. In addition to the three that you've pointed out here, CMS has noted there are over 60 PBMs across the US. Therefore, the competition, there's many options for the employers that are out there, government entities, as well as unions to choose from given their specific needs. 1:10:35 Sen. Debbie Stabenow (D-MI): So when we look at Express Scripts has 100 million Americans covered, CVS 90 million, OptumRx 65 million, Prime Therapeutics 27 million, Humana 21 million, and yet Americans still pay the highest prices in the world. Even though you are negotiating for millions of people. The VA has its own pharmacy benefit manager service, they negotiate for 9 million veterans, and they pay, on average, 40% less for the same drugs that the rest of the healthcare system pays for. Despite greater volume, you are unable to secure these kinds of low prices. With all due respect, you guys are pretty bad negotiators. Given the fact that the VA can get 40% less. And so I'd like to know from each of you why that's the case. Dr. Miller? Steve Miller [Former EVP and Chief Clinical Officer, Cigna Corporation]: Yes. Part of the equation is giving patients choice. At the VA, they actually limit their formulary more than any of us at this table do. So oftentimes, they'll have one beta blocker, one ace inhibitor. And so if it's going to get to that level of choice, then we could get better prices also. Sen. Stabenow: Let me jump in, in the interest of time. I know you create nationwide drug formularies, you have pre-authorization, you give preferred status to certain medications. So you don't use any of those tools that the VA is using? Because you do. Steve Miller: We definitely use those tools, but we also give people choice. It's crucial for both physicians and patients to have the choice of the products they want to be able to access. Many of our plans want us to have broad formularies and when you have more products, it means you move less market share. Sen. Stabenow: So basically you're saying a 40% premium gives them more choice. 1:24:30 Sherrod Brown (D-OH): If the administration's rebate rule were finalized as proposed, would you in some way be required to change the way you do business? Mike Kolar: Yes, Senator we would. John Prince: Yes. William Fleming: Yes. Derica Rice: Yes. Steve Miller: Yes. Sen. Brown: Thank you. 1:25:05 Sherrod Brown (D-OH): What percentage of prescriptions that you fill across Part D actually receive a rebate? Roughly what percentage? Mike Kolar: So Senator, approximately 8% of the prescriptions that we cover in Part D are associated with a rebate. Sen. Brown: Okay, Mr. Prince? John Prince: Senator, I don't know the exact number, I know our overall business is about 7%. Sen. Brown: Okay, thank you. William Fleming: About 7-8%. Derica Rice: Senator, I do not know the exact number but we pass through 100% of all rebates and discounts. Sen. Brown: [Grunt] Steve Miller: 90% of the prescriptions will be generic. Of the 10% that are branded, about two-thirds have rebates. So it's about seven-- Sen. Brown: 7-8% like the others. Okay. To recap, PBMs do not set drug prices. Forcing you to change the way you do business -- as the administration's rule would — will not change that fact. And while the rule might impact a small percentage of drugs and Part D that receive a rebate, it does nothing to lower costs, as your answer suggests, for the other 90% of prescriptions you fill. Most importantly, absolutely nothing in the proposed rule would require Secretary Azar's former employer or any other pharma company to lower the price of insulin or any other drug. It's important to establish that, so thank you for that. 1:41:40 Catherine Cortez Masto (D-NV): Let me ask you, Dr. Fleming, in your testimony, you say Humana's analysis of the rebate rule -- and we're talking about the administration's rebate rule now — found that approximately 17% of beneficiaries will see savings at the pharmacy counter as a result of this rule. Can you tell me a little bit more about who these people are? And what kind of conditions do they have? William Fleming: Senator, there will be a number of members who are taking brand drugs for which we get rebates and so it could vary all the way from the common chronic conditions, things like diabetes or hypertension or high cholesterol, all the way over to occasionally, not usually, but occasionally on the specialty drug side. When you think of some medications like treatments for rheumatoid arthritis, multiple sclerosis, places where there's competition. Cover Art Design by Only Child Imaginations Music Presented in This Episode Intro & Exit: Tired of Being Lied To by David Ippolito (found on Music Alley by mevio)

We begin our series on fellowships discussing the fundamental differences between residencies and fellowships, introduce the basic types of fellowships, requirements of a fellowship and what you should do now if you are potentially interested in a fellowship. Fellowships are highly individualized postgraduate programs that are designed to prepare the fellow to become an independent researcher. Thus, the majority of time spent during training is honing these research skills versus patient care skills that are more typical of a residency. Key Take-Aways: Fellowships may be 12-months long, but often are 2 or even 3 years of training. Some fellowships will require residency training prior to entrance in the program as a pre-requisite, but some may not have a pre-requisite and may be completed right out of pharmacy school depending on the type of fellowship (industry vs academic) Fellowships are highly variable and all offer very unique experiences, so it is important to do your due diligence up front to research the pre-requisites, activities, and outcomes for each individual fellowship Check out our https://www.postgraduatepharmacist.com/ (website) where you can search our episodes, blog, merchandise, and ways to join the SASO squad. Follow us on twitter https://twitter.com/PGPharmacist (@PGPharmacist) or on https://www.facebook.com/PGPharmacist (Facebook) and https://www.instagram.com/thepostgraduatepharmacist/ (Instagram) @ThePostGraduatePharmacist and leave us your comments or questions that we did not answer. Music | "Sweet" by LiQWYD Watch: https://www.youtube.com/watch?v=eIYlaVPdNYM&t=0s (https://youtu.be/eIYlaVPdNYM) License: https://www.youtube.com/redirect?event=video_description&redir_token=QUFFLUhqbDdvMzd1WktadWZDQzJTTjhhcUR6UDRtWUNIUXxBQ3Jtc0tuZEdZRV9aQnp4UnRkbGFqaFgyVTRsTVZBRURRem5vNWFYNHpPMXZpTkVQdGFkaktaMi1kTlB6TWliNG04OW5FLTJSa1VXOERvSC01RHluTDYxY3AtSHEwVkpIOU9jSmdfdkZEUVpCc2NPZWMxbHBPcw&q=https%3A%2F%2Fwww.liqwydmusic.com%2Fhow-to-use (https://www.liqwydmusic.com/how-to-use) Download/Stream: https://www.youtube.com/redirect?event=video_description&redir_token=QUFFLUhqa0Vxdi1ycThfdkdJWHJldzJlY0Q4ejJBUVVrZ3xBQ3Jtc0tsY2hPdGV4Rkx6TVpPb3FKaURlclJna1RBV3kwVTlIcGJmRHdyUGVaY09CQm5MMHJHWDY1VnhrTDRLSDNBM2ZpbDlFZHcyTzhrbTNYdEMyYzFIZ1RtZE1OTmQ4dTI0UWNRRjhRRjkxNUFtdmVsR3plaw&q=https%3A%2F%2Fhypeddit.com%2Flink%2Fun7fp7 (https://hypeddit.com/link/un7fp7) References: American Society of Hospital Pharmacists. Definitions of pharmacy residencies and fellowships. Am J Hosp Pharm. 1987; 44:1142–4. Albert E. Fellowships 101: Q&A with a Residency and Fellowship Director. Pharmacy Times. https://www.pharmacytimes.com/view/fellowships-101. Published 2015. Accessed June 10, 2022.

This week on Pharm5: AAPI patients underrepresented in clinical trials Camzyos (mavacamten) approved for obstructive HCM Voquenza (combination vonoprazan products) approved for H. pylori Pharmacy job postings up 18% in 2021 Implications of potential overturn of Roe v. Wade References: Asian, Indigenous, Latino patients underrepresented in US clinical trials of Biologics. Healio. https://www.healio.com/news/rheumatology/20211208/asian-indigenous-latino-patients-underrepresented-in-us-clinical-trials-of-biologics#:~:text=Asian%2C%20American%20Indian%2C%20Alaska%20Native,research%20letter%20published%20in%20JAMA. Accessed May 5, 2022. Camzyos Prescribing Information. accessdata.fda.gov. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214998. Accessed May 5, 2022. Cosdon N. FDA approves 2 vonoprazan treatments for helicobacter pylori infection. Contagion Live. https://www.contagionlive.com/view/fda-approves-2-vonoprazan-treatments-for-helicobacter-pylori-infection. Published May 3, 2022. Accessed May 5, 2022. Staff PT. FDA approves pair of Vonoprazan treatments for helicobacter pylori infection. Pharmacy Times. https://www.pharmacytimes.com/view/fda-approves-pair-of-vonoprazan-treatments-for-helicobacter-pylori-infection. Published May 4, 2022. Accessed May 5, 2022. Pharmacy Demand Report (PDR) 2021 Yearly Summary - aacp.org. https://www.aacp.org/sites/default/files/2022-04/pdr-2021-yearly-summary.pdf. Accessed May 5, 2022. Roe v. Wade live updates: Protests rage on over leaked abortion ruling. NBCNews.com. https://www.nbcnews.com/news/us-news/live-blog/roe-v-wade-live-updates-protests-rage-leaked-abortion-ruling-rcna27427. Published May 5, 2022. Accessed May 5, 2022.

On the Shelf is hosted by Joanna Lewis and features conversations about wellness including nutrition, supplements, skin care, and anything else on the shelf! In this month's episode, Joanna talks to Jill Murphy from Pharmacy Times about what to expect from this podcast.

In the latest episode, Alana Hippensteele of Pharmacy Times sat down with Kelan Thomas, PharmD, MS, to discuss potential adverse effects and drug-drug interactions that pharmacists should be aware of with psychedelic medicines. 

On this episode, please tune in to hear Jovin and Sean interview Dr. Bailey Scism on her journey from pharmacy school in Kansas to a PGY1 Community Pharmacy Residency at the University of North Carolina Chapel Hill to a PGY2 Ambulatory Care Residency at AdventHealth Celebration.    Please check out Dr. Bailey Scism's article posted on the Pharmacy Times titled: Is a 90-Day Supply the Best Option to Improve Medication Adherence? (pharmacytimes.com).

In this episode, our guest is Dr. Jamie Wilkey is a pharmacist who loves what she does and brings passion and happiness to the pharmacy profession. Jamie grew up in a small town in Wyoming where she got her start in pharmacy working at the local City Drug. She attended the University of Wyoming School of Pharmacy for her Doctor of Pharmacy. She was active in student government while at UW and also served as president and later as vice-president of her pharmacy class. For 10 years post-graduation, Jamie worked in community pharmacy while having and raising her 4 little boys. Frustrated by the stress and schedule of that position created her own job for herself that better suits her talents, her passions, and her family's busy schedule. She abruptly jumped out of retail and into the world of entrepreneurship and has found her true calling in life. She is the founder & CEO of Arches Health, LLC. She serves patients in her community as a consultant pharmacist focusing on pharmacogenomics. After getting her practice up and running began to empower other pharmacists to do the same. She teaches pharmacists in her online program & active network called PGx Consulting Confidence Academy to confidently champion PGx and create their own consulting practices that bring the flexibility, freedom, and satisfaction they are seeking from their careers. Just this year, she has taught over 160+ pharmacists how to change their careers. Dr. Wilkey is a member of CPIC as well as the nonprofit organization GTMR, and ASCP. She has been featured on over 15 podcasts in the past year, on Pharmacy Times, Kajabi, and was recently voted as one of the Top 50 Most Influential Leaders in Pharmacy. Jamie is optimistic about the future of pharmacy and knows great things are in store for those pharmacists who are willing to push boundaries, to think big, and to use the full extent of their education. Main points: - Tell us about your leap from community pharmacy to entrepreneurship The two-five main points I'd like to highlight: -entrepreneurship within pharmacy -pharmacogenomics -create new leaders in our field -the changing role of a pharmacist Guest - Jamie Wilkie Dr. Jamie Wilkey, PharmD, RPh Founder, PGx Consulting Confidence Academy CEO, Arches Health, LLC Host - Hillary Blackburn, PharmD, MBA www.hillaryblackburn.com https://www.linkedin.com/in/hillary-blackburn-67a92421/ @talktoyourpharmacist for Instagram and Facebook @HillBlackburn Twitter If you want to join a free session to learn about setting up your consulting practice for PGx with Jamie, go here: https://7kvp9t8n.pages.infusionsoft.net/

This week on Pharm5: AMA against pharmacy-based test-to-treat Expanding pharmacist roles Kaleo's naloxone auto-injector E-cigarettes increase odds of pre-diabetes 2 years later, COVID-19 deaths hit 6 million Connect with us! Listen to our podcast: Pharm5 Watch us on TikTok: @LizHearnPharmD Follow us on Twitter: @LizHearnPharmD References: AMA statement on Administration's test-to-treat COVID-19 plan. American Medical Association. https://www.ama-assn.org/press-center/press-releases/ama-statement-administration-s-test-treat-covid-19-plan. Published March 4, 2022. Accessed March 10, 2022. March 9, 2022 president Joseph R. Biden the White House. https://www.ashp.org/-/media/assets/advocacy-issues/docs/GRD-Joint-Pharm-Org-Letter-To-WH-on-Test-to-Treat-2022. Accessed March 10, 2022. Sartain M. CDC makes the case for pharmacists' reimbursement given expanding roles. American Pharmacists Association. https://www.pharmacist.com/Pharmacy-News/cdc-makes-the-case-for-pharmacists-reimbursement-given-expanding-roles. Published March 7, 2022. Accessed March 10, 2022. Ashley Gallagher AE. FDA approves 10-mg naloxone injection to treat exposure to ultra-potent weaponized opioids. Pharmacy Times. https://www.pharmacytimes.com/view/fda-approves-10-mg-naloxone-injection-to-treat-exposure-to-ultra-potent-weaponized-opioids. Published March 4, 2022. Accessed March 10, 2022. BioSpace. FDA approves Kaléo's 10 mg naloxone auto-injector for the treatment of known or potential exposure to ultra-potent weaponized opioids. BioSpace. https://www.biospace.com/article/releases/fda-approves-kaleo-s-10-mg-naloxone-auto-injector-for-the-treatment-of-known-or-potential-exposure-to-ultra-potent-weaponized-opioids/. Published March 2, 2022. Accessed March 10, 2022. The surprising truth about prediabetes. Centers for Disease Control and Prevention. https://www.cdc.gov/diabetes/library/features/truth-about-prediabetes.html. Published December 21, 2021. Accessed March 10, 2022. Rizzo S, Nirappil F. Global covid-19 death toll tops 6 million, another grim milestone in the pandemic. The Washington Post. https://www.washingtonpost.com/health/2022/03/07/6-million-covid-deaths/. Published March 7, 2022. Accessed March 10, 2022. CDC Museum Covid-19 Timeline. Centers for Disease Control and Prevention. https://www.cdc.gov/museum/timeline/covid19.html. Published January 5, 2022. Accessed March 10, 2022. Holder J. Tracking coronavirus vaccinations around the world. The New York Times. https://www.nytimes.com/interactive/2021/world/covid-vaccinations-tracker.html. Published January 29, 2021. Accessed March 10, 2022.

Dr. Jamie Wilkey talks about the PGX Consulting Confidence Academy, which focuses on the business side of running a pharmacogenomics practice.  Pharmacists don't have a lot of business training.  So, if you're interested in creating your own pharmacogenomics practice, this episode will have a lot of value for you. Read the full show notes at https://www.thepharmacistsvoice.com for the highlights of our conversation. How do pharmacists use their voices in the pharmacogenomics space?  How do they learn the science of PGX?  How do they start their businesses and get paid?  My PGX Pharmacists Series has given me the opportunity to learn from Dan, Sue, Mariam, and Jamie, and I have really enjoyed our conversations! (See episodes 133, 135, 137, and 139 of The Pharmacist's Voice ® Podcast)   Dr. Jamie Wilkey is a pharmacist who loves what she does and brings passion and happiness to the pharmacy profession.   Jamie grew up in a small town in Wyoming where she got her start in pharmacy working at the local City Drug. She attended the University of Wyoming School of Pharmacy for her Doctor of Pharmacy. She was active in student government while at UW and also served as president and later as vice-president of her pharmacy class.    For 10 years post-graduation, Jamie worked in community pharmacy while having and raising her 4 little boys. Frustrated by the stress and schedule of that position, she created her own job for herself that better suits her talents, her passions, and her family's busy schedule. She abruptly jumped out of retail and into the world of entrepreneurship and has found her true calling in life. She is the founder & CEO of Arches Health, LLC. She serves patients in her community as a consultant pharmacist focusing on pharmacogenomics. After getting her practice up and running began to empower other pharmacists to do the same. She teaches pharmacists in her online program & active network called PGx Consulting Confidence Academy to confidently champion PGx and create their own consulting practices that bring the flexibility, freedom, and satisfaction they are seeking from their careers. She has taught over 160+ pharmacists how to change their careers. Dr. Wilkey is a member of CPIC as well as the nonprofit organization GTMR, and ASCP. She has been featured on over 15 podcasts in the past year, in Pharmacy Times, on Kajabi, and was recently voted as one of the Top 50 Most Influential Leaders in Pharmacy.   Jamie is optimistic about the future of pharmacy and knows great things are in store for those pharmacists who are willing to push boundaries, to think big, and to use the full extent of their education.  Thank you for listening to episode 139 of The Pharmacist's Voice ® Podcast!   Mentioned in this episode PGX Consulting Confidence Academy Arches Health, LLC Dr. Jamie Wilkey (LinkedIn) University of Wyoming School of Pharmacy Dan Krinsky, BS, MS, RPh, FAPhA Sue Paul, RPh Mariam S. Yasin, 2022 MS PGX and PharmD Candidate The Pharmacist's Voice Podcast Episode 133 featuring Dan Krinsky, BS, MS, RPh, FAPhA The Pharmacist's Voice Podcast Episode 135 featuring Sue Paul, RPh The Pharmacist's Voice Podcast Episode 137 featuring Mariam S. Yasin Women Business Center of Utah (SBA - U.S. Small Business Administration) Kajabi article about Dr. Jamie Wilkey's successful online course Own Your PharmD Dr. Karen Brown PGX for Pharmacists Podcast on the Pharmacy Podcast Network  Todd Eury (Pharmacy Podcast Network Founder) US Small Business Administration (SBA)   SCORE Business Mentor Organization  University of Toledo College of Pharmacy (Toledo, Ohio GO ROCKETS!)   Subscribe to or Follow The Pharmacist's Voice Podcast! Apple Podcasts Google Podcasts Spotify Amazon/Audible Highlights from the interview It all started with LinkedIn.   After 10 years in community practice, Jamie Created a LinkedIn account. Once she connected with other pharmacists at the beginning of the pandemic, she saw what was possible for a pharmacist to do. She couldn't go back to community practice.  She knew she was capable of so much more.    Having conversations and sharing ideas over time gets results.   With more than 15K connections on LinkedIn (as of February 2022), Jamie is well-connected.  As time goes on, people seek connection with Jamie, and she invites others to connect.  Jamie posts consistently on LinkedIn.  It has drawn a following and has been rewarding.  She has found her tribe and people with similar ideas.     Learning the science and business of PGX Jamie learned the science of PGX through certificate programs.  Learning the business of PGX included trial and error, talking to others who were 1-5 steps ahead of her, and using free resources through the U.S. Small Business Administration (Women Business Center of Utah).    Time management is important. Once Jamie started working as a PGX pharmacist in a clinic, she shared about it on LinkedIn.  A number of pharmacists reached out to her privately, asking her to coach them and help them.   In the early days of her PGX practice, Jamie's time was limited due to her private practice caseload and family commitments.  She knew she couldn't work individually with pharmacists.  As an alternative, she created an online course and “dumped her brain into it.”  She has earned more than $200K with her online course.  She recently passed her clinical PGX pharmacy practice on to one of her students, which allows her to spend more time with family and updating her online course.   Serial entrepreneur Since founding the PGX Consulting Confidence Academy, Jamie has also co-founded Own Your PharmD with Dr. Karen Brown.   A typical work week Jamie works three days/week:  Monday, Tuesday, and Wednesday from 5 AM - 7 PM.  Mornings are for projects.  Afternoons are for meetings.  Thursdays, Fridays, and weekends are for her interests and her family.   Setting the vision Entrepreneurs set the vision for what they want their lives to be like.  Setting boundaries makes it happen.     Features of the PGX Consulting Confidence Academy It's a self-paced online course with live weekly online meetings.  Students learn the business of PGX (not the science). The goal is to help her students build a profitable business and change patients' lives.  Students can consume the content as fast or slow as they want.  The weekly online meetings are for Q&A and discussion about successes, stumbling blocks, and more.  There is also an interactive, private social media group.  According to Jamie, the online community is an uplifting place to be.   Prospective student info There are ~160 lessons (as of February 2022) and ~50 hours of content.  New content is added regularly.  A simple, two page blueprint gives students an overview of the course and helps them navigate it. The Academy has ~ 170 students (as of February 2022).   According to Jamie, the investment is approximately $4,000-5000/year.   Click here to learn more about the PGX Consulting Confidence Academy.  On the website, there is a free webinar, testimonials, and a link to schedule a call so that you can determine if the PGX Consulting Confidence Academy is right for you.     There's a new podcaster on the block! Jamie is the newest cohost of the PGX for Pharmacists Podcast on the Pharmacy Podcast Network. Todd Eury (Pharmacy Podcast Network Founder) invited Jamie to be a cohost.  According to Jamie, PGX for Pharmacists Podcast on the Pharmacy Podcast Network is the 9th most downloaded genetics podcast in the world.    Jamie isn't good at being grumpy.   Jamie has a positive attitude.  She believes that it's more fun to be happy than to be sad.  There's a smile in her voice.     Moms are amazing!   “If you want to get something done, ask a busy mom to do it, and they will get it done…and, they will do it efficiently!”  Jamie has four boys under the age of 10.  She's busy and only has time to work on what is important and will move her forward.  She doesn't have time to procrastinate or be a perfectionist.  She runs her life lean and doesn't make excuses.    Finding balance  At first, Jamie didn't have systems and processes in place.  To grow and get to where she is, she put in the time to figure out what worked for her.  It led to more flexibility.    What advice would you give yourself 9-10 years ago as you were working full-time as a staff pharmacist in a large chain retail setting? Start putting your voice out there.   Start sharing your thoughts and value with the world. Ex:  Create a blog. It's easy to pour your whole self into job or family.  Put time aside for yourself, who you are, and what you love.     Speaking engagements If you're interested in inviting Dr. Jamie Wilkey to speak at a conference or event, contact her via LinkedIn.  Jamie cares about expanding the pharmacy profession's reach and empowering women.     Thank you for listening to episode 139 of The Pharmacist's Voice ® Podcast!  

ADHD -  attention deficit hyperactivity disorder - is a condition characterized by differences in brain development and brain activity that affect attention, the ability to sit still, and impulse control. It affects millions of children and adults and has far-reaching effects on the lives and well-being of these individuals. And yet we still don't know what going on!Is it genetic? Is it environmental? Come and listen to learn a little bit more about the neuroscience of ADHD and what's going on in your head. Please rate, review, and subscribe and if you have any questions, comments, concerns, queries, or complaints, please email me at neuroscienceamateurhour@gmail.com or DM me at NeuroscienceAmateurHour on Instagram.Citations and relevant pictures below:Demontis D, Walters RK, Martin J, et al. Discovery of the first genome-wide significant risk loci for attention deficit/hyperactivity disorder. Nature Genetics. 2018;51(1):63-75. doi:10.1038/s41588-018-0269-7Faraone SV, Larsson H. Genetics of attention deficit hyperactivity disorder. Molecular Psychiatry. 2018;24(4). doi:10.1038/s41380-018-0070-0Froehlich TE, Anixt JS, Loe IM, Chirdkiatgumchai V, Kuan L, Gilman RC. Update on Environmental Risk Factors for Attention-Deficit/Hyperactivity Disorder. Current Psychiatry Reports. 2011;13(5):333-344. doi:10.1007/s11920-011-0221-3Oscar Berman M, Blum K, Chen TJ, et al. Attention-deficit-hyperactivity disorder and reward deficiency syndrome. Neuropsychiatric Disease and Treatment. 2008;4(5):893. doi:10.2147/ndt.s2627Quist JF, Barr CL, Schachar R, et al. The serotonin 5-HT1B receptor gene and attention deficit hyperactivity disorder. Molecular Psychiatry. 2003;8(1):98-102. doi:10.1038/sj.mp.4001244Zulauf CA, Sprich SE, Safren SA, Wilens TE. The Complicated Relationship Between Attention Deficit/Hyperactivity Disorder and Substance Use Disorders. Current Psychiatry Reports. 2014;16(3). doi:10.1007/s11920-013-0436-6Tomasi D, Volkow ND, Wang R, et al. Dopamine Transporters in Striatum Correlate with Deactivation in the Default Mode Network during Visuospatial Attention. Rustichini A, ed. PLoS ONE. 2009;4(6):e6102. doi:10.1371/journal.pone.0006102Ritalin Poses Cognitive Risks to Those Without ADHD. Pharmacy Times. https://www.pharmacytimes.com/view/ritalin-poses-cognitive-risks-to-those-without-adhdSupport the show (https://www.patreon.com/neuroscienceamateurhour)

This week on Pharm5: 2022 ASHP Match Rankings now open Pfizer-BioNTech COVID-19 vaccine on hold for kids

The COVID-19 pandemic caused massive disruptions in pharmacy schools, and even once some classes resumed in-person, students had a myriad of barriers and motivators to attend. To learn more about these impacts, we spoke with Cara Rutledge, a student at the University of Texas at Austin College of Pharmacy, who researched class attendance during the pandemic. This episode also features Carolina Mussenden, a pharmacy student at the Nova Southeastern University College of Pharmacy who is simultaneously pursuing her MBA. Mussenden discussed the importance of leadership positions as well as finding balance between academics and extracurricular activities. Are you interested in writing for Pharmacy Times? Reach out to AAntrim@pharmacytimes.com to learn about various opportunities to get involved!

Dr. Ed Cohen is the Executive Vice President of Pharmacy Advocacy for MJH Life Sciences, the largest, privately held healthcare media business in North America. He works on behalf of pharmacies and pharmacists to bring them information and ideas that can enhance their practice and impact their patient care services. Prior to this, Dr. Cohen served as the Senior Director of Clinical Solutions for Walgreens and as the Director of Pharmacy Operations for Safeway Corporation. In addition to his corporate experiences, he has held several faculty positions and earned numerous professional certifications and industry awards. Dr. Cohen has also made major contributions to the content direction of Pharmacy Times magazine as a member of its Editorial Board. He holds a Doctor of Pharmacy degree from Midwestern University and a Bachelor's Degree from the University of Illinois at Chicago. Connect with Dr. Cohen today at https://www.linkedin.com/in/ed-cohen-pharmd-fapha-9385016/ Are you a healthcare professional or healthcare executive looking to advance your career, build a better brand, or create a leadership legacy? Iqbal can help! Schedule your FREE CONSULTATION today at https://atchainternational.com Connect with Iqbal on: - Linked at https://www.linkedin.com/in/iqbalatcha/ - Instagram at https://www.instagram.com/iqbalatcha1 - Twitter at https://twitter.com/IqbalAtcha1 Join us next week for another exciting episode of the "Healthcare and Higher" podcast! #HealthcareAndHigher #IqbalsInterviews Song Credits: "Life Is A Dream" by Michael Ramir C. "Stay With Me" by Michael Ramir C. --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app Support this podcast: https://anchor.fm/iqbal-atcha/support

About Dr. Blair Thielemier, PharmD: Blair Green Thielemier, PharmD is an independent consultant pharmacist living in Arkansas with her husband and daughter. Blair is preparing the next virtual pharmacy conference, the Elevate Pharmacy Virtual Summit. She is also the founder of Pharmapreneur Academy, an online e-Course and Community where she guides pharmacist-entrepreneurs through the process and barriers of building a pharmacy consulting business. She is the author of How to Build a Pharmacy Consulting Business, a contributing author for Pharmacy Times and guest host on the Pharmacy Podcast Network. More information about Dr. Thielemier can be found on her website. https://www.btpharmacyconsulting.com/ Pharmapreneur Academy https://pharmapreneuracademy.com/pharma-academy/ Learn more about your ad choices. Visit megaphone.fm/adchoices

About Dr. Blair Thielemier, PharmD: Blair Green Thielemier, PharmD is an independent consultant pharmacist living in Arkansas with her husband and daughter. Blair is preparing the next virtual pharmacy conference, the Elevate Pharmacy Virtual Summit. She is also the founder of Pharmapreneur Academy, an online e-Course and Community where she guides pharmacist-entrepreneurs through the process and barriers of building a pharmacy consulting business. She is the author of How to Build a Pharmacy Consulting Business, a contributing author for Pharmacy Times and guest host on the Pharmacy Podcast Network. More information about Dr. Thielemier can be found on her website. https://www.btpharmacyconsulting.com/ Pharmapreneur Academy https://pharmapreneuracademy.com/pharma-academy/ Learn more about your ad choices. Visit megaphone.fm/adchoices

Pharmacy Times Continuing Education (PTCE) provides industry leading pharmacy CE to retail, oncology, managed care, specialty and health-systems pharmacists. They use multiple deliverables in the live, virtual, on-demand, and print formats created by in-house pharmacists to deliver tailored multi-specialty education. Educational Objectives: Discuss the various barriers to COVID-19 vaccine uptake including reasons for vaccine hesitancy Review how pharmacists can address the reluctance of COVID-19 vaccination in communities Faculty: Rachel Armstrong, PsyD Clinical Psychologist Portsmouth, NH Rachel Armstrong, PsyD, has no financial relationships with commercial interests to disclose. Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hours (0.05 CEU) under the ACPE universal activity number 0290-0000-21-283-H06-P. The activity is available for CE credit through July 29, 2022. This activity is supported by an educational grant from Janssen Therapeutics, Division of Janssen Products, LP. See omnystudio.com/listener for privacy information.

In this Episode of On Script, Jeremy and Jessica interview Dr. Sarah Carpio, PharmD, Dr. Joanne Canedo, PharmD, and Valerie Wasem from Touro University California College of Pharmacy to discuss expanded pharmacy technician roles in a post-pandemic landscape.  As two recent PharmD graduates, and a current second year pharmacy student, Drs. Carpio and Canedo, and PharmD. candidate Valerie Wasem started their pharmacy careers as technicians prior to being admitted into pharmacy school, and have continued to work side by side with pharmacy techs in multiple settings.  These guests recognize the value that technicians bring to pharmacy practice, and the importance of continuing to move forward with advancing pharmacy technician practice.  Finally, we discuss an article they coauthored for the this year's Pharmacy Technician Supplement from Pharmacy Times entitled “Postpandemic Future is Bright for Technicians.”  See omnystudio.com/listener for privacy information. Learn more about your ad choices. Visit megaphone.fm/adchoices

In this Episode of On Script, Jeremy and Jessica interview Dr. Sarah Carpio, PharmD, Dr. Joanne Canedo, PharmD, and Valerie Wasem from Touro University California College of Pharmacy to discuss expanded pharmacy technician roles in a post-pandemic landscape.  As two recent PharmD graduates, and a current second year pharmacy student, Drs. Carpio and Canedo, and PharmD. candidate Valerie Wasem started their pharmacy careers as technicians prior to being admitted into pharmacy school, and have continued to work side by side with pharmacy techs in multiple settings.  These guests recognize the value that technicians bring to pharmacy practice, and the importance of continuing to move forward with advancing pharmacy technician practice.  Finally, we discuss an article they coauthored for the this year's Pharmacy Technician Supplement from Pharmacy Times entitled “Postpandemic Future is Bright for Technicians.”  See omnystudio.com/listener for privacy information. Learn more about your ad choices. Visit megaphone.fm/adchoices

In this Episode of On Script, Jeremy and Jessica interview Dr. Sarah Carpio, PharmD, Dr. Joanne Canedo, PharmD, and Valerie Wasem from Touro University California College of Pharmacy to discuss expanded pharmacy technician roles in a post-pandemic landscape.  As two recent PharmD graduates, and a current second year pharmacy student, Drs. Carpio and Canedo, and PharmD. candidate Valerie Wasem started their pharmacy careers as technicians prior to being admitted into pharmacy school, and have continued to work side by side with pharmacy techs in multiple settings.  These guests recognize the value that technicians bring to pharmacy practice, and the importance of continuing to move forward with advancing pharmacy technician practice.  Finally, we discuss an article they coauthored for the this year's Pharmacy Technician Supplement from Pharmacy Times entitled “Postpandemic Future is Bright for Technicians.”  See omnystudio.com/listener for privacy information.

Join US!! https://cpha.com/event/dhx-virtual/  The 3-day experience will connect YOU with others unified in the mission to contribute to a healthier society.  Telehealth, remote patient monitoring, and precision medicine are rapidly transforming how health care is delivered and consumed. Join us as we explore opportunities to leverage digital health technologies and solutions to augment the care we provide today and shape the future of health. During the conference, you will hear from industry leaders, digital health innovators, and visionary futurists! We invite everyone across the healthcare ecosystem to join us as we collectively explore health, well-being, and medication optimization through digital health integration. The possibilities are limitless as converging technologies are rapidly catalyzing the movement from health care to health. DHX Virtual will be covered by Pharmacy Times and Pharmacy Podcast Network.  2019 on the First DHX Summit w/  Dr. Parisa Vatanka, PharmD, CTTS about the Digital Health Conference held by the California Pharmacist Association (CPhA).  https://omny.fm/shows/pharmacy-podcast-network/the-digital-health-conference-2019-ppn-episode-864  See omnystudio.com/listener for privacy information. Learn more about your ad choices. Visit megaphone.fm/adchoices

Dr. Christina Madison, PharmD & Dr. Leslie Asanga, PharmD, MBA, MPH talk about the mission of delivering public health with advance technologies embracing mobile applications, pharmacist's oversight, and collaboration with physicians.  About Dr. Christina Madison, PharmD Dr. Madison is a past President of the Nevada Public Health Association who has been asked to share her clinical public health and infectious disease expertise with Local, State, and International Media outlets and NGO's. She has an intimate knowledge of the impact public health messaging, policy, and legislation can have on communities. A trusted and valued health care professional with 13 years of experience in Public Health and 16 year's experience as a pharmacy professional. She has received multiple awards and recognitions including recent recognition by Pharmacy Times' as a “Pharmacy Hero” in May 2020 for her patient education and pharmacy advocacy during COVID19. She has also been recognized for her patient counseling skills and public health/vaccine advocacy and leadership including Silver Syringe Awards in 2010, 2013, 2014, and 2015, Public Health Leader of the Year 2014 from the Nevada Public Health Association, One to One Patient Counseling Award by Pharmacy Times in 2012 and 2014, and most recently being inducted as Fellow of the American College of Clinical Pharmacy for her sustained contributions to the organization and profession of pharmacy.  Dr. Madison is currently an Associate Professor of Pharmacy Practice with Roseman University of Health Sciences (RU).   She completed a pharmacy practice residency at the New Mexico VA Health Care System in 2005, she obtained board certification in ambulatory care pharmacist (BCACP) in 2011, has been credentialed with the Academy of HIV Medicine (AAHIVP) since 2013, and was elected Fellow of the American College of Clinical Pharmacy (FCCP) in 2018. She maintains two active clinical practices with Huntridge Family Clinic, which focuses on the LGTBQ community and is one of the largest providers of HIV prevention and gender affirming care services in the State of Nevada as well as Volunteers in Medicine of Southern Nevada (VMSN) where she offers immunization and communicable disease care. Dr. Madison actively participates in both state and national pharmacy and healthcare organizations to facilitate awareness of healthcare policy, education, and advocacy. She is the Founder and CEO of The Public Health Pharmacist, PLLC a public health consulting firm. Currently she is helping individuals and businesses navigate the COVID19 global pandemic, providing Public Health PR Plans for getting businesses back in action and prepared for the next hurdles. Advocating for change to improve the health and wellness of vulnerable populations and the underserved is her passion and mission.   https://www.thepublichealthpharmacist.com/about  About Leslie Asanga, PharmD, MBA, MPH  Dr. Asanga is an experienced pharmacist and recently graduated from Yale University with a Master of Public Health degree. While at Yale, he took courses in Public Health Entrepreneurship, Startup Founder Studies, and Sustainable Innovations in Healthcare at the Yale School of Management. He is the CEO and co-founder of UrPharm which won the Thorne Prize at Startup Yale 2020. He also holds a Doctor of Pharmacy degree from Roseman University of Health Sciences and an MBA with more than five years of healthcare experience. He is an innovator and passionate about creating healthcare ventures that create impact in vulnerable communities. https://www.pills2me.com/#/team  See omnystudio.com/listener for privacy information. Learn more about your ad choices. Visit megaphone.fm/adchoices